UvA-DARE (Digital Academic Repository)
Sickle cell disease, pathophysiology and clinical complications
van Beers, E.J.
Link to publication
Citation for published version (APA):
van Beers, E. J. (2008). Sickle cell disease, pathophysiology and clinical complications
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s),
other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating
your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask
the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam,
The Netherlands. You will be contacted as soon as possible.
UvA-DARE is a service provided by the library of the University of Amsterdam (http://dare.uva.nl)
Download date: 18 Jun 2017
Sickle cell disease,
pathophysiology and
clinical complications
Eduard Johannes van Beers
!"#
$
%
#&
&#
&
# '#'
#
#(
"$
%
( "$
%
)
#(
"$
%
*%( +,!-+ -+ ..++-/
0
#&(
#12
#
3#-1#
40
&%
1
56#
$"$#
1
7
8
56
#
%
&
9& !:( ##
"#
$
%
&,:+,+;
1
1(
-(
(
16;$
4
%$%
$%
11<
10$6#
1%
1%)='&
166)
0
#3#
CONTENTS
Part I: General overview and clinical complications
:
.
/
1
1
-
####
#
-#
8
-
#
(
#&#
#
#
#
,
:
.,
/+
#
-
'
#
>.
8&
#
?#
,,
Part II: Pathophysiology
9
>
Part III: Pulmonary hypertension
, )
#-8#
&#
-
#
! #
&
'
#
+ '
#
: #
#
&
#
#
:: ?
#
'
: #
:. '
:/ ###2
+:
: 9
::,
:+
:/+
:>9
:,,
:!9
Part I:
General overview
and
clinical complications
Pathophysiology and treatment of sickle cell disease
(Based on: Ned Tijdschr Geneeskd. 2005 May 21;149(21):1144-9)
1,2
3
1
E.J.van Beers , M.Peters , B.J.Biemond .
1
2
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
Department of Pediatrics, Academic Medical Center, Amsterdam.
3
Abstract
!"
"
"
# !
#
"
"
$
"% % " " "
" ! " "
" &# ' " "
" (
" &'"%
%"
"
&)(
Introduction
+,- " ./,+&%
-%,
/
+&-% , $ +&, &$- &
+&0
- ! , " "
%
"
""
" !
#
1
"
" 2 % "
#"1
# ! # / , 3
(45
4
Epidemiology
,"
%'
6(%.( ( " '
' "
+&-7((
8 ( 497 6 (% . ( 5 . 3
% : ' 3
(
& 6 ( ;
3 ("(<
(9
'6('"
57
7"
=!
',3
99 4
Clinical presentation
/ "
" % "
#% % % # % "
<97',#"
" ' ' 1 &'"%"
"1
/
"
"
""
%
%
"
% % % . %
*
'
%
2
'
# % % % 1+
- (97
','
597 ' +<>.- ( +%"-
' ' ? ( ' % "
"
" ' #
>
%''=97
',"
+&!-
'
'
!&!
# +32- " "
(
1
/ "
1
+
%
@;%#5%99-
9
Pathophysiology
!
+&-
A
B
, +-.
"
% ' ' "
#
'
"%
%
%"%
" Polymerization of HbS
,
!
'
'
/# !
/&
!#
/
#
&
+&C- *8
"D
&C &&C
'&
'',
#
.%
& / & '";
Endothelial activation and increased adhesion
>"""
,
( / % "% " , 8 # # "
/ & &'"% " % '"
"
1
%
/&
%'
"
! 1 " !% "
, ' "
"
9% ! "
"
% E "
" %
"
'#
.(<%F(<%$
%
" 5 . ,% "
#
"
/ " #
"
%= !
" % % , Vasoconstriction
3 # +32-% % "
'
,
%#
', !
"32
32% 1
' )
%32 4
. 32 ' "
# 32 ! 32 "
#" # , "
32 '
"
" &
"32
"
Coagulation activation
',"
"
C
# #
" "
.
%"
# , *,%""""
1"
"'
, 5
Treatment
Pain
( "
"
"
" "
"
'
1
' , / % 3(.,% '
"
" 8
1'',"
8
' " % % &'"%'
%
B
:"
" "
" ! %#
Transfusion therapy
E
#&
"
, +
-&'"%"
% "
G
> E % ' .
# &7 H=97 %"'
'
"
'"
' ,
! "
9 0
""""
# "
' "
" 59
=
(
•
(J
0
"1"
•
(
•
(
•
"
•
•
>
•
,
•
#
•
C"'
"
•
+"-
•
>"
•
Screening, prevention, vaccination and antibiotics
(
499
',3
'
",
@599 .%
',
""""
59
(" & .
/ '
#
'
, Hydroxyurea
(
/
'#1"
" ' , 55 3# &C% # " ' " "
32 C% " ' # "
5=I%497#
5=C%##
,
'
# &
%/
+/#-% " " # &C ! %
#
"
Anti-inflammatory and anti-adhesive drugs
( % " 1
# ' 4
"
'
%'
"
1
%
%
"%
"
, /%
%#
""
, 54 ( / # 5 ! "
" ' , ' &'"% ' "
" ''
5 " KF=
%"
, =%5 ( " ',#
'
( % #% ' ,
"
" 5
Stem cell transplantation and gene therapy
!%
"
"',
,"1"
+>.!-'#
"%
+
97- " = ;" (
""
%
&'"%#
'%
"#
"
Conclusion
,"'
# $
, (
'
, '% # 6#
' , " &'"%
/,
" '
' "
'
C "
"
This thesis
!
J
!"
+=-%/"
"+5-#
'
"
" + 4- 5 ! , "
"
+ - = ! "
%
+
- .%'
/
+(- " "
" , + 5- 3#% ' "
'
1 "
" + =- !
% ' "
"
'
''"
1
'
,"
"'
+4-
.%%
, "
" ' " . #
% ' "
" #',
. % / ' #
=97 ','
.%'
' "
/ "
"
0"
.*%'
,
#
"
"
#
''&!9""
1
"
'&! .%
'#
',#
Acknowledgment
!
'
References
5
=
4
*
9
5
=
4
2%E
,@%>6C%<
C%2%<&%
<
.
,
)$#>C$
, 3$
@<**4@*L==9+5=-J=*44 ,( .J$&%&
>%<3%<&% J
3'IJ>"L**4 =*4 &: &% !'
" ?% <% G <% @% & & $ : / $ G/0 ( < ( 3 !:
;599L4+=-J** ;%E"<@%&"
) (
1'
: " 3
&
5994L5+4-J5* <%3
> !)59942*L=4+*445-J=4=9 ,
<%&
(%
)%<GF%C
E%2
"3%
'
E
599=<L9+-J5494 F$%3),%$
(3%6
>%)$!%,,%
3
(; 3$
@<5999
@55L=45+5-J ;
'<!%"F%@<)%/I%
@C%<G%
&>
C,'
, 3$
@<5994C5L=9+*-J* E&C !
, 3$
@<**L==+-J5* G
,G% C <$% C% > $<% 3
>) . "" %
"
#
@
."
**,L*+-J54= !(%6)(%<3%
E%C "
J(' 3(5995<L**+-J=94 "(%)I%E'%%6$%&
> "
3$
@<**3"5L==+55-J4*9 $ &% < 3<% >: % < !3% 3 !% ,' E(% ! "
' "" E
5994 3"
L94+9-J== > ,% 6 ?% ! @$% & 3% >2% ...% (3% #"
3<5995,L+5-J==* ?I%,'F)%,'!<%&%M'@) 3##
#
#
: 3(**@5L*=+=-J9
4
$
% E I% & @% !' (% G
(% 6 >% F" J""
" (@&
5994@
L+=-J54 ( G.% 2 $ &
J # ! ( @
<599=,L+*-J5 E3I%>(G%<@ !
J
E
599,
L*+5-J=55== *
59
5
55
5=
54
5
5
5
5
5*
=9
=
I%!%"G%(!!%C@6%<
(E !#
J
/
@
E
**53"L*+4-J*=44 G<%E)%6
,%<'(%E@ '
(/" 3$
@<*,L=*+55-J445 6G 3
/ 3!:;**@5L4+4-J4 % ! <)% < >,% ," ;@% E CE% $ F% $ # 1
."<
&#
( 3$
@<**<L==5+59-J=55 <&%EC%2%
'&%E
G%G
(%
$#
J * @(<( 599= (
5L5*+=-J4 G
,G%)?%%E
@,%F
;<%&
> (
"
' ( @ & 5994@
L5+-J&5*=&=9 "((%
"(3%&@%&
> <
"
J
E
599(L*+-J*=4 ; !% <. ,% E ;> &, ." <
! (
'
, 3$
@<**4<L==9+-J== E
@,%<&%6
!$%F
($%
G<%G
F%
>
$
("&#.F
!
< (@
&
599@5L99* E%"(%<(%<
<%((%;> $3
(@&
599=<L=+-J5=5 <>%GC(%)%'3%@%F$%
(J"
#
E@&
59993"L+5-J4*99 6 ,)% & )% E % (E% E
(% E ( .
3 2# ( F
" 6 , @(<( 599= <
L5*+*-J=45 F
&
E
>"599=L+=-J= *
59
Patient controlled analgesia versus continuous
infusion of morphine during vaso-occlusive crisis in
sickle cell disease, a randomised controlled trial
(Based on: Am J Hematol. 2007 Nov;82(11):955-60)
Registered trial: ISRCTN74336585
1,2
3
1
4
5
E.J.van Beers , P.T.Nieuwkerk , C.F.J.van Tuijn , P.W.Friederich , J.H.Franken ,
1
B.J.Biemond .
1
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
Department of Medical Psychology, Academic Medical Center, Amsterdam.
4
Department of Internal Medicine, Academic Medical Center, Amsterdam.
5
Department of Anesthesiology, Academic Medical Center, Amsterdam.
2
3
Abstract
!"#
$
" $ %# & ' '(
$ ) ' * $'
+ $# $ "
"
"
"
,"$
-""
$ $ " . / 0 1 0
2. .. 33 4. 5. .6 $ , $ "
'1 -/ 3 ,"
$ 6 5 . .1/ 3. 1/ 5 . . %# 3 $ "
' &
"
'
"
Introduction
7
,
'$ " ' " ' $ ,
&
$""'$$$'"
" )$ /8 " ' " %& "
' " $ $ " $$ ""
0 $ 9# $
$ & 3
$#$:
#
##$ ;#'
$ $$
"
"
"
$"
$
' 1 ,# " #'(
$'*#'$"
3</ #
"
"
#"
$
' " # "
' 4
,$"
$
+ " ! " " # "$"
("
'
' 3
Methods
Subjects
,+
"
;
#
9 , $ " '$ " " & " ' $ "=!'#!'#!'>.!'>?<
'$
" < @ $ '$ " )# '
# '# # # ' )
)
'$ - "
A
"
# " /.. 4 $ /. 3 $# " , ' '1")
/.. 4 $ /. 3
$ B)
$""$
1
"
Study Protocol
" + '" " C # D# ;# E$< ( " '& "
$ 7+ " '
) "
#
$ "$+
' ' # " ' & '
.5
# . 5 " " & 3.<3 "
$ , $ '
" , '" F'"$
"
.5#..5"
+ ' (
/ " '$ ' . . 0 , " ''$'"
"
' 1
;)'$/
'
/ &#'"
. .0"
/ $
'
' ' (
/ " '$ . .3 00 '$ "
""
0
& " ' '
' , " 0 " " *& 9) $ # /.. 4 $ /. 3 $
" "
/.#3$
'"
Outcome
, $ " $ #
$ " G$##&$"
$
!$
$ " $ " $"'
,
'
"$
" $+ 3 D
)
$ $ #$
$#
# " $ '" $ " $ 33 $# ""F#".H
I H I .. H$ I H
$
I# $ ' &$ "
'"$+'"$ J$
" ;
K
$ 34 % ! $
%34 31<3/
%34"$
!$!
;!$;!
$
JG
Side-effects and adverse events
#
##"
$
.5$#.5"$ $"
/
. , # " / ,
&$
)
#
L
" ; )$
" $ " ) < # 9M L " $ "
"$
)$
#
N36 /O#
$#"+
34
"
'&"
$ 4
Statistical analysis
" $ $ D
)
'$#
"$+
")
$$ "'(
'
" ' ' " $
$""$
A$+
L(
)
,#L'"&
'"' ' JG " $ " '$ '
"
$
JG'
$
$ & J7 #+
$ " /.8 $
'" A". -.#"
$ "'
$'$+ / A" @
Results
Patients
,"$ - " $ ,"
+""
&"
+% ,'
,''""
"
')
$
/ @@ 6 3@ -3 1
#
$ !+$"
$'
603 60 # $ ; '#(
#"3 @83 8
% $)$ "
' K ) " # "
, '" " 9
$
9 %P
!$)$P
!'$
P
P
>P
,
3
/.33
@
@31
@
6
3
6
3
D'
!'0G
/ 6/ 34 -
G
$
).-0G
/ @@ 6
98
@3//@-
0G
@3 @ /
!'%8
3 @ 6 !'8
@1@6/
"& P9' 6
/ /1 1@ .
3@ -3 1
4/.@6
- . 4. /
3 1 -
@64-.
Morphine dose and duration of treatment
,"
$" ,$
". /. 3. 40 1 1
1 0 2. ..< ""33.464..1
/-<5. .6<,' ,"$)'$#'
$
#
1 /3 34 . $ @ ./ .6 / $< 5. "
" $ 2. .. $
$ . /. 3. 6 0 3 / .1 /02. .. ,
' 1 -4 $ ) '
&
,"4 .1 3- 3$
- .4 . . $ 5. / " $ . /. 3. 60 / /1 @
0 < 2. .. , " $
''" "
,
;
;0
,
;'
1 11 4..1/-
1 -3 -/ 6
. /. 3. 4
33.46
/ 31 /4 -
. ..
. .6
. .-
;
LP
9
63//
3
. .1/
1/34/-
3..1.
. .
1.6
/./
. 1
433
6..
. /
"& P5$
L -
Pain and Quality of Life
, " ' " $ % D ' " 1 3 / # 1 -3 -/ 6 " / 61 /4 , $ # "
# 1 3 1/ 6# / 31 /4 - 4 3/ /@ 6 $ 5. 1 5. .-
5. 3- , " $ " / 1 3/ 6 1 -3 -4 -5. 6/ D
"
''
#/-/6/@4361
'
" $ " ' $ 1/@ 36/ 1 &$
','3 ,"
$
'" #
"
!
D
"$
F
/-/6/
@4361 1/@
36/1
F
-6-3..
-64--6 -
@.
F
3-3/3
16-/ 611
/3/
PP
..
. .
. @-
J$GP
$
!$
333@
134 ./
@-
. -1
;!$
1.31/4
113@/4 1@1
1-
. -1
'& P5%!$%34PP5
"$'"
Side-effects and adverse events
,L)
"
"
$363//5. .1/3..
1. 1/34/- 5. . ,' 9 $ "
( "
'" " ; )$ "
$-6-/--8-@-1-68 K)
$) $ ) ," '
$ " $ D 3.
$ " % " ' " + " "
' + 9 & $) "
=;0" 1 11 . /. 3. 4
2. .. D='
"1 3 / 1 -3 -/ 6
"
/ 61 /4 ,
$#"
#
1 3 1/ 6#/ 31 /4 -4 3/ /@ 6
$5. 1#5. .-5. 3- 3
Discussion
F
" + '$ & + "$
$"
"
"
'/
$# " '
,)
L
" " ,
9
"''" ,
"'E++ "
" " $ (
)6#
"$ @ D$#
'"" "4
"
" " "
''
$+#
$# " " ' " ' 6 ' ) #"
)"
$# $ ' '$ ' !"#
""
-.
A$+&$
'
9 &$ " ' '" $
"
"
" " , $ " )
' #$
" ) $ ' H (
'I , '$"
($"$$" $
#""")
3
""" $
"
)
) $
,
$'
$"
$ ' ' ) &$ " '" 3<1%#
/ /
# " ,"'
" /@,
'$ $ ' !$
$# '
" 6$#"
"$
"'
$+"' $&
%$#+$
$ ' !"# '
# # $ $ $
%# $ ) ' $ ' " $ '+""'"
" $ $ -.
$#
$
'$'
''(
' ,$# " $ , " " & # " $ " $ "
" $ !"# " $# $ #$""
"&
&$ " $ ' & ""
33
Reference List
3
1
/
4
@
6
-
.
3
1
/
4
@
6
-
31
K#D'M#7A%#;%#K#';! ;$
GB)
$7%
B$ 9BM;--1<33.3=43-411 D!% ,
9BM;--@<33@=@4@4- # K G %$ "= ; " D;M --@<
3/@.-=4/444. Q
$ B# M
' # M # Q E $
) $
,..1<@/3=1.14 9 ! , < , A= , 9 ! 9 !# D# G
#..=/-@1 7# D Q ' $ 7 ..4< -<=..33/. E++ B7# D 9# ! G# A # D # K M (
$ ;--</@=3@33@6 ,9K#Q
$;Q#GE "
"
M9--6<3=/- ! G# 9$ ;# G ;B B M$;--<4=11 ;
;# D# ! !% $ $
--<143=4/4- D' B# G # $ G# D % R
= S %7--</=1@-163 7 A# K" !# $ !# Q ;,# MG D
" =
)$'
--3<
=@1@- %# D# , %# D # &
F R S ;
--3</-.=/3/3. $ B# 7' # ; 9 " " '
"'$
DM--3<@/[email protected]@3 $B#!#;9 ""'
"
'$
DM--3<@4=666 D$7M#A;#FM#Q$M ;
$
--4<4=-31 "M#G'%#MM#G'E#D(7#7$% ,
$
'$ --/<31=1/31/6 $ ;# T ;D# KU ;# 7%# " % $ --4<
3.3=1@ MA# D !# # !( ' !# D" M# ; B# ,'' =+
---<-3=3/1 .
3
1
/
4
@
6
-
3.
3
3
33
31
3/
34
E ,# L
!# E T# K+ ;# D
K# ,
; '
$ M..1</@=@6@ $
#'' ="$
$
$ DM$
--6<3@=313/3 BQM A'V
V =%%;#KEA#DE#
'#;=D
"
'
#..@=@4 D;,#F7%#!7A#%E!#!#ED !
A
..1<1/=@6. ;)"Q#$#D B)
=&$ D;M---<36@-6=/6//-. DD#GD;#WM#9%#7 =
+# " M--<63=14.144 D$ 7M# A ;# F M# Q$ M# A ; '' --4<4=@ K"!#Q;,#MG F'
1=
'
+'
--.<1/6=4-4 '$E;#!E;# ='$.. --6</33=4 K#,D#D'M#;%#7A%#F
$B 7
9BM;--<3/=4 ! # # M# , M ' " B;%..3<//4=11114 Q B# M!# + 7M ; = -6<.=116 M
' B# ;" # ;# D$ MB# ," ;# $ G $# # &$
"
..3<.=6@-3 %M,#DM#DG $
K
;=F
$ M$;..3<//=1.41 AMB#M #' ,;K34$%34 "
;--<3.4=1@3163 A MB# Q ; # Q %34 $
; $ = LU; D#;=,#9"B;
#../
F
$B#9$G#B9#A7#GB,# $ 9 $ $ E 9 B M ;
...<31/=6//64/ 3/
34
Sickle cell disease related organ damage occurs
irrespective of pain rate; Implications for clinical
practice
(Based on: Haematologica. 2008 May;93(5):757-60)
1,2
1
3
1
E. J. van Beers , C.F.J. van Tuijn , M.R. Mac Gillavry , A. van der Giessen ,
2,4
1
J.J.B. Schnog and B.J. Biemond
on behalf of the CURAMA study group.
1
2
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
3
Department of Cardiology, Acadenic Medical Center, Amsterdam.
4
Department of Hematology, Erasmus Medical Center, Rotterdam.
Abstract
!"
#
!$
#
%&
&
%!'()
%
!*%
+
&
% ,- ,)-
%
%
!.
+ !
Introduction
% &%&%
%!
0 % *& &
! 1 # + !'"
2
"%
2
&
!,0
!*%
3&
!4
%
2
!5
2
!) 4 % 3 % #
!
/
Design and Methods
Patients
4
*
4
6
46 4
% &! 4 &
% % #
7 ,((8 & ,((9 &%!.%
&
%&
46
% *!
SCD related manifestations
#
%
&
%
%:
; &; <!8 ; <,!8
%,)%
&
<(;,)!8
='(( ; >
!9? + % .@A B,!8 ; & !C*.%
&%
.@A!:
#
!/ <,( 1 % 2
!'( &
!
<'(((D;E
<,( !'' ! &', &% 7
,((,#7
,((!!
F#
!"
%2
!
!!#&6
@
3.
!
Pain rate
C
%
& & #
;
&
%2
)7
,((,
7
,((
3
:
!C
%2!
)(
Laboratory parameters
4 &
% &
) % & ! G
& *&G-
%
&
#2
'
α#
%
%
2C@
!')
Statistical analysis
. *&
*&H(#
%
%
*& *&HI#
! %
J@!1%%
%6
#"K!
%&%
% GL 02
.! 1
% & ! C#
&%
(!(8%
!C',!(!,C
E%
!
)'
Results and Discussion
$ % & % 9 % 2 '()
.
&'!
5
4
G
-
1
*
&;E
@-
EO'(/;E
G
*
&-
E
K;E
;E
$
-
6
&
@
C
@
C
*&M8/;
H(#
M8
9)
,,'#)'
9
*&M,/;
HI#
M''
)(
,/,)#
9(
CN
(!9)
(!//
/!(!'#/!
!,8!/#'(!/
/!(!,#''!
!'!#')!9
(,/'#8'
8'),#8
''!'(!9#',!,
,!,!,#!
9!/8!/#!/
'!'!(#!,
,,'/(#,9,
98#
=(!(('
=(!(('
(!(('
=(!(('
=(!(('
=(!(('
)
,
,)
')
'
99
8
',
9'
')
(
,
(!(('
(!)(,
(!()
(!(('
'!(((
(!((9
=(!(('
-
4
E
4
5&;
:
#
#
#
C
-
'9
')
,
,
)
,
''
,'
(
'
)
,(
(
9
(!,,
(!(',
(!'9
(!),
(!(),
(!,(9
@
!N6
#"#.%#G#2
!
),
4
%%
*&;*&HI#
% *&;*&H(#
!C*.%
,-
',-*&#*&H(
*&;*&HI
% .@A ,!9( ,!8(#,!9/ ;! 5 C*. .@A<!(
;! 4 % 2
#
%
& &% % %
2
!
%!
4
4
%
%
&,!.
&%
&
&
&
5
!'8 &
C*.%,-
,)-
%
! G C*. &
% ,- '(- %
!.
4
8
%&
2
! % & !
.
+
9'(('
&
%
#
!
&
!G
%
8 % % %
! . & 2
& 2 & 8 ! &
!.%
&
&2!*%
#
)??'9#,
! . % & 2
&
!,)4
% #
!,8 E
&
!5%
!
C*. #
&
% !
)
#
%&
!
5
4
#
-
2-
*2
-
$
-
6
&
@
C
@
C
-
4
E
4
C
-
(
5!;
(#'
))
CN
,
,
)
'
)
)
''
,8
8(
9
9
(!',
(!8'
(!(')
,
,)
)
'9
9
,
,'
/
,
/
'
9
)
,8
)
'9
8
9
,)
8
(!/(9
(!'/
(!9')
(!9(,
(!9
(!()'
(!((,
'
(
/
/
'
9
(
,
8
,)
)(
',
))
(!('/
(!8',
=(!(('
(!(
(!()'
9)
9
9
,
(!,)'
(!,)'
>-
*&;H(#
8
*&;HI#
)
5&
!NC#
&
!
B'
Reference List
'
,
)
8
9
/
'(
''
',
'
')
'8
'9
'
'
'/
,(
P
>7>
%6.&6*! :
&!1@,((?,'':#)!
77E
E@@+@4
+GC6G4 47!5%
!47*
'//?8':9'#99!
6
04& 0Q
Q6>
.6C%@*
7
!
:
!17
*
,((?',,:8/#98!
C
$.1 1
&
76CG@"GA0
!C
!
@
!5076'//'?,8':''#'9!
1
47! &
!@
&##
&
! &
'///?,,,:(#'!
6
4>+
>@!@
)(%3#
!167
@0'/'?,,9,':'''#''!
C
$1
&
7@"G6CG
$&6*
!6
##E02
@G
0
!5076'//)?(,:'9/#'9))!
>
% 6. A 7 6E 3
Q C 7G 6 P ! C
* @G
C
% !5076,(()?8(/:9#/8!
" C G GE P @0 E CC 4
6 ! C & & ! $
,((? ''(/:'9#
'9,!
6
1 1
C" 2 E 66
E! $ % !
7
C
$
'///?)':,#,!
G11
&
P
46A0"
"
!E
: C .
4
.$C! 7 C
*
$,((,?,)):,)#,/(!
6715Q!4:C
@
.
!1
'///?/)8:'888#'89(!
$5@E!@
&
&
#2
*CE!'//?
/8:,(#,)!
.
4J
.E%C!4

#
!1,(('?/':,8(#,8'!
71 476G4*@+@41
+ C!
?
%!
576,(()?9,'(:9)#)!
C%
@ E * 4 @
0 7 ! $ : )#
&
'(89
!61
,((8?)9:9#9!
$1
&
7.1@4@1>C
!.
: ! . ! 1 '//)?
),:9)#9)/!
G%707!P6&6P!C
%&
:
!7K'//'?')8':98#9!
$#G P " 7 E4 6 . 0& 6 7" ! &
:
!1'//?/'':,#,/)!
C%
@0#6
E5
7*4E$
E6
!
:
!46'//'?''8:9')#9,(!
)8
,'
,,
,
,)
,8
)9
"
.6*
&@+
>@!>
:&
.7
!7C
,(((?'9':(#8!
6 CG P
4C & 7 E4 P4 0& * ! !5076'//'?,8,':')9#')'!
P60
@P
4P
4C7@1@
!E
%
RS!1'//?)):')(#')(!
4
P$0C!@
&
!47*
,(((?9):,(8#,''!
% 6 *
& @ 0E E 5 +
>@ 1 4! : &
! $
,((8? '','':'9/#
'8!
)
)
Normal sublingual microcirculation during painful crisis
in sickle cell disease
(Based on: Microvasc Res. 2008 Mar 12. [Epub ahead of print])
1,2
3
1
1
3
E.J. van Beers , P.T. Goedhart , M. Unger , B.J. Biemond , C. Ince
on behalf of the CURAMA study group.
1
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
3
Department of Physiology, Academic Medical Center, Amsterdam.
2
.
Abstract
!"
""
#$
!
%
%
&' ( %(
(
( ( )
* )
$(
"(!+*,
%-
(%%
(
& " ( ( " . +*, / " "
"%(&
0
+*, ( 120/ &
+*,(%1.0/
+*,
1.0/ ( +*, "'!%(
"
("%'"%3)4-531(
6 % ( "% Introduction
7)"
8
%%(
8
!%
& $ ")" , ' (
%
'$
"8"$%!
%
"'$%
"% % # $ ! %
%"%
")"
%'
'($%"%%'"
% " /)5"%'
%"9
" 8" 2)4
& 59 $ 5 ( $ "9 % ( "% ( % % & $ % $%
%)/
, %' ( ! % ( "% % )
* * ' "
"5/)/.
/
Methods and materials
Patients
" /. % :' :' :;)
:;<)
(#
+#
'
= ( # ( % (!(("
,%/)>',,%)2,,,%.)/5(
( ! 5 " ( %
( "% % ' ( ( , ' % " ( " & % (
"%
"(
&%((:
Measurement of sublingual microcirculation
& ( %9 * +' +7
#
' & = % / , ' *)' ' % * ? @
((">
'(
%
% %% & (
%
!
/%,"
%
( " % A)1 5 & % " ! % !
*
"
(%"(
&
%' +" ( ! +*, (
&
(+B6(B+"+B"/'"
1
Microvascular flow index (MFI)
&
"(!+*,"%
)$"%
( "% " /4 7
*("$/#,$
" ( " 2)/ C
' /)1 C
1)C
/D*%
%
1
(*("%%%""(
% " 9 (E E (' /E (' 1E
('>E
(E%%
(&
"(
"
9"+*,(
$"
5
"
(%9
" # ( % " %%
( "
%
("
+*,'(("%'"
+*,'
"(
(
"%/
(
" " $,',,',,, ,7 " % 9- ?>-
F1G
'
+1-/)1G
'
>-2)/G
"
Inter and intra observer variability
#%*"
(""%%
%
!"%9*"
D
" ( ( " +*, , " "% (
%)%9
*"
(%%
"
>
Statistics
& " % +*, ( (
()
@&)#=7#&
""%(
%
%D#
/#
((%
%95/116(B1+1
Results
Patients
& . :' 1 :' > :;<)
/ :;)
'
>.0/>%".
%(/
" ( % " "%(
4
4
3
MFI
MFI
3
2
1
2
1
0
0
Crisis
Steady state
Controls
Day 1-3
Day 4-6
Day 7+
*1E++"*(,!+*,(%
% % = +*, ( ( *>E++"*(,!+*,(%/)>
>%
'%)2%.<%(=+*,(
(
Microvascular Flow Index (MFI)
&
"("%!+*,
% 12 0 / 1. 0 / 1 , ' ( +*, % 1.0/ +*, $ % >
#(''(
"(
"% ( ' ! % %%
( " % " ( " ' ( " ( "% ( "%
( " 3)4- 531 "% ( %
3>4-53/%
"3/.-531.
"(
(("%
3)>2.-5314*H
"%%'
" ! ( ?:
(=(
"("%
((
Inter- en intra observer variability
& )" "% "
(25I/2.5I/"%D#
@
)>/ 1/ )2 > & )
" "% " ( 4>2 5 3 / 4/ 5I/
"% D #
@ )>4 > J.. .
*E&
""(E('(/'((1'
(>%%
(K&L
((!
" " 0 = % ( " ( * E ' ( " ( "% ( "% (
"3)4-531ME&(((
"
+*,
2
Discussion
, %' ( " ( "% ( %(($'*
'"9
/)/. , ' % ( %9 = " ( "% ( " ( %(%"
("%!%+*,('(
('
!%%%
(
(
&
"?((
( "% ( %
'%"4
( " " "("%(
("%?("2-46
!"*%'($"
%(
% :("' % $ ! *
$%"
$%"5"%
%/.-1%'$
"(
%"
"
"(:("'
% " ( " 2N (%'$
((+*,
> /N " ( "%2 , ' (
("(%
&%' % ! % " ( " ( %
"(
""("-//-/>?%'%
%
" % ( " 9
,%'(
"("%
"% " "
( ( " & " ( " ( "% 8 ( " % "
1/
&("("(&
%
%
%(
("%?(%.-4
.
6 % ( "% $%"%
4
Reference List
/
1
>
2
.
4
/
//
/1
/>
/
/
/2
/.
/4
/
1
1/
%:'+=+'A
8
'+%&='=&'(D# &
5) " ( %% "" D 1-
//E>>.4)>>4
% :' + =' 59% ' 5' #&6 , "" ( O,"/-/>2E/)1
P P' *% + ' *' A +' = A? , "" )
' " !% O ,"/-22E14)14>
&#'6?#'+='D'*55
%%
"E#(
5=#11-E>.)>/
6 P' : A5' Q = 5) % % " #
O 5% : 5%1-142E:/24):/2/
#&6'5R'? '5?'A
8
'&*+"
E
)"
%%D11-//E>)
#&6' :
9 5' 6 &' 5R' ? ' #
AO " "%' % %' ( 8"
" "%' % ) " %' D 1/-
.//E>/)>
?(%::'=H'P9+,"
%%
%
O,"/4.-4/E//.)/1.
5 ','Q+O'+PA':+'S*=%
""
&?11->2>>E/>)/>2
5 'A
O:'',&
%
E"
%
&
:
12->E.2).4
R'+O'D'O'7O?5
%(
(+1->1E/41)/4>/
D ' O' +O' R' 7 O? +" ( "#
:O1-/./E/)
D'O'5O'+O'7O?+"D*(,#5
(#
OA+11-/22/E4)/
5*#','D
QO)
"9
" % 9 =%
12-/E/2.)/./
, & 1- E/>) -N1 #
1E/>)/
, E " $ " 1-/E5.1
Q 6' 6
O6' : #Q' , ' D
QO' +
P 9
E(
%
=+/-/E/1)/1/1
D
'+PA'"75:'5 ',T%)"
% E " " % 1- 2EA2/)
A22
D O+' #
Q ( ( ?/42-/4.2E>.)>/
+PA'7P'DP'QO'H&',
5
"%
%%
O#5%1/-//E.).4
7% ++' ?(% ::' P =' 9 ' # " !% +"A/4->1E/)12
2
Part II:
Pathophysiology
Circulating erythrocyte-derived microparticles are
associated with coagulation activation
in sickle cell disease
(Submitted)
1,2
3
3
3
3
E.J. van Beers , M.C.L. Schaap , R.J. Berckmans , R.Nieuwland , A.Sturk , J.C.M.
4
1
Meijers , B.J. Biemond on behalf of the CURAMA study group.
1
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
3
Department of Clinical Chemistry, Academic Medical Center, Amsterdam.
4
Department of Experimental Vascular Medicine, Academic Medical Center, Amsterdam.
2
Abstract
!! " #$
" %
!
"
&' (
# &
)"
"*
" !'
+
$*
# &
% # !
' (
", # &
#" -&+++$ ./0'1 - 2$ ./
3'41$
"
##
#
*
'5
%
& * " !
# " "
$ '
' " 6%7'0$
&87'77 67'39 &87'77$ ! :
# "
#
! 67'9 &87'77$ %"
" #"
;. 67'9
&87'7767'39 &87'77$
!
"
# # !'
("
"
#&67'9&87'77'2% "#
<+ " 71 &87'77$ *
% " # =++ *
##
!
&>7'7' (
)
# # <+ * * %
!
&67'79&67'7'
:
)
#<+%
# %
!
&'
Introduction
" " "%! #* # ! "'+$"
!$
' 2 " %
#$
"
"!
" %
"' 2 "$
)" " &?@A%
"$
"
!""' 9(*#"
" # #
&
) '
&
! ! # %
!
"
& ' & " "
"
!
#" B C ! $ & #" $ $ ' 5
!
"
# &!
##
#"!
#
*
! !!
"
'4% (
) "
" *
&
$*
!
$
" '(
",# &
#"
" !
) #
&#
"
)#"
*
#
! $ *
"
) # # (; "
%
!
&'49 2 "
# "
" * & ##
! " # !
"
#
*
'
+ $ *
# & * # $ )
* $
#
!'
Methods
Patients
!
@$ @A7D.%
" @$ #"
* #"
E "$ "
* # 2
" 2 2"
" *
# ' 2 # * #
"#
"
#
)
"
$$"
$
$
*
)
'&
*
!
"
!
"
)
"
# & # ' &
# *
!
"
E ! 'F
*
#
* # #
# *
' 2 !
*
#"
* !
!
*#
2'(
*
*
#
#@
'
Collection of blood samples
F"
*
#"
!
* E 3% * ! "' F * ' "G 7'7 ##
" F
$ H
$ 2' : " #
$ *
"!
# #7" 7)7I'&""
*
!
7'"GE $""
#
E %07I'
Reagents and assays
; ;+(%
+-$ &5%
+-$ 7%&5$
%&5 4%&5 *
#" F
H
$ 2$ +-%&5 #"
+"" J & -
$ (
?
$ % ;+( #" &"
H
$ 2$ %&5 &%&5 #" F
" +' ; $ 2$ 5%&5
#" 2
F$ ?$ 7%;+( #" " -*$ ?H$
%;+( #" 2"
+' "#$ ($ %;+( #" 2
)
F
" $ 2 % 2 #" 2KL - $
"' ;$ 2&%, ) = * #" F "
$ 2'2%# =++$ %# <+ %(;&+ *
#" E 2"
"$ (
?
' 2 *
#"
" # &"
" &%
+"" MN "9 $ ?$ O2' &
*
"
*
%7772!92G
9
@#$ (
?
' # !$ # ! " #"
;. ;. 5$ F
$ $ -
"9 !
:
;=:;%
#"2KL$- $
"9%"
92
"
%$M
$2"
$
?
*
"
5G+2
Isolation of microparticles
2"
#7PG#
"**
"
#
# #7
" 0'037)7I
&'2#
# $PG#
* "!
' (
" *
PG %
##
""DG ?$ ' ""DG $ 7'3 ""DG
"
$@4''2#
# #7" 0'037)7I$PG#
*
"!
'(
&
*
*4PG&F%
'+
$ # "
& *
' & "'4
Flowcytometry
;!
PG#
& * PG'""DG%&F'(
PG 2&%
) = * PG # %
# "
%"
' (
"
*
# " "
"
'2#
$377PG# "%&F*
)
) = $ * 377 PG % &F * '
"
*
#
" # "
;2 *
J #*
F
$ H
$ 2' F #* ; *
*
"'&*
#
#
%
#
)='2
)="
"
*
# %# ' G
* %
# " *
# # %"
" #
%"
!
!
#"
!
!
'
Thrombin generation
(
" (-( * ! ' F
#$ & *
#
%
" &%#
"' ; )
"
$ #
" & *
# 7 " "
"
*7QG#
#=++<+$ # * (;&+$ !
' 2%# =++ * )
* %# <+ * #) <+%
"# ' &" & *
#
# 4
7" 4I'("
*
67#7QG
'4 ""DG # ' 2 #)
!$ QG%E *
"!
4QG
%*"
"
&
#"
(@%&
"$F
$*
"
# #
"' 2#
" $ 37 QG "DG *
!
# &
#"
(@%' (
" # %
* "
R 6 7 " * ") "
!
$ O
$ 2' ; E !
$ *
)
"
!
2O$ #
"
!
*
7" #
#
'
Statistics
*
)
"
* %E +JM'
F
*
##
*
* %:
O :) # ' "
' ##
*
#
*
%E ';
"M
##
*
"
'(
#
# " $ *
")
"
* ,
'M
#
"
$*
##
'&%! ≤7'7 *
#' * #"
&
'7'&+$$+G'
0
Results
Patients
2 # !
* # *
$ * !
"
' ; (
' (
"
# "*
#
!
" "
$
# '
?
;
"
1
2
-
S
@
A7%
A.%
@
F"
@
"""DG
M
1
("
)73DG
G
)73DG
G
ODG
S? "
#
*
#
'
&# %
7
0
F
0%0
'7'%'
''%'7
434%74
3'03'7%'0
400%4
'0'%'
4''%3'0
3%
0''%'7
04%
Numbers and origin of microparticles
%E "
#& # (
' + *
$ ", # & #" . 2. .' 2 # #
4.%
) & * $ & #" "
. .$ .$ 5. *
$ & ) (;
#
'
(
"
# & *
# "
#
" G@ "$ ! !:;%$ # %"
! ;.$' (
%
!
& . #& *
"
# $
3
&# F
&
&)7D"
''3%3'
''7%4'4
7'4
&
#&1!
#/
4
''%4'
-2
3'4'%'
0'40'0%3'7
'7'3%'4
'0'%4'
3'03'%3'7
7'
7'0
7'73
# !/
;."DG
74%
%"
QDG
73%0
!:;%1
30%4
S
# "
#
!
*
'
%0
7333%7
4%
7'7
7'7
7'7
*
# * "$ G@$ # "
(
'
# & #" !
$ '
' & ) &%
& $ ##
# *
# &67' &67'$
!
'
(
# & # *
%
!
&
.$ * * G@ 67'3$ &87'77 @ 6%7'0$ &87'779 (
'
5
%
!
& *
* "
# !! # ! *
! (
9 ; ' 4%!
& # 2 *
* "
# *
(
'
&
#/
-2
4
@
""
/
@
"""DG
G@ODG
M
1
&
)73DG
%7'0SS
7'3SS
7'
7'4S
7'70
%7'4
7'7S
7'SS
# !$#
!/
!:;%1
7'SS
%7'74
;."DG
7'SS
%7'74
%"
PDG
7'SS
%7'7
2! "
##
'S&87'7SS&87'77
47
%7'
7'7
7'4SS
7'SS
7'77
%7'7
7'
:
& *
#"
! *
4$ "
#
B
!
C
#*"
'F#"#
B
!
C
##
'2
E $
#&##
*
*
#
!
'(
!
* # & 2
) = !
" # &
!
# !
/ ;+(%
+- +-%&5 * '
"
5!
*
$ *
*
# & #" "
$ ) (;
*'
!"#
*
2.&"
#!!
!!:;%2$#%"
$
!;.'T%<%)
"'SS&87'77'
"
$
# 0'037)
77'777)4
?
0
5!
&%
7D"
&S7D"
5!
&%
!
#2
)=1
0''4%7'
''7%4'4
40'04'%0'
'4'3%'
7'747'7%7'
''%4'
? "
#&7D"!
#SS/
''00%4'7
7'77'7%7'7
-2
7'7'7%7'
7'77'7%7'74
4
7'7'%7'7
7'77'77%7'7
S
&
#
2
)=!
!
&%
'SS
#
'
4
Thrombin generation
(
#
"
; '(
2O#
"
!
$ " # " $ * "
# & M67'$ &87'77' (" * ##
%
* % " # =++ # %(;&+ 19
&67'7'+$
#%#<+$"
%#
&87'77'(
)
#*#
* "
#
%
!
&67'7$&67'7$ *
%
!
&
%
!
&6%
7'7 6%7'7$ !
9 &6?' 2 ##
" U2O
*
)
"
** #<+
*
"
#2.&67'$&67'779
"$; '
%
&!"#
'
()
; /(
"*
"
/4E #"
)
2O#
#&
#"
#
&%#
""'(
B(;&+C$B<+C
B=++C*
##
#
&% "
'; /
*
"
#2.&
)
##"
% "#
<+67'&67'77'T%<%)
"'
4
Discussion
:
# "
* # *!! !$
"$#
!'
;$*
"
" &*
!
#"
$
"
#&##
#
*
$
# * "
%
!
& * !
# '
(
* ! ! "
# %
!
&
%
!
&
*'490; "
$*
#
!
#&
)4$
#
$ 2'
(
4. & *
* "
# "
#
#
#
" '32#"
&$
# & #
""
'+
$ "
%
!
. %
!
.$ .$
5. & #
' 2$ & ) (; *
#'
(
#
*
! $**
#
% "
%
!
& ) (; 4' &$ ##
)
" # #
%
!
!
"
!
':
*
77$777)
$ *
!
* # %
!
!
$ !
&#""
$#(;$*
#
'
:
*
!
*
"
# & !$ %
!
& !
# * !! $
#
!'(
!#"
! #
*
" &?@$ * *
" " '97" !$
'
"
"
#
&%
) * !! "
# !$ # !$ *
* * &%
) ' !
$ #"
%
!
& *
"%
!'
+ " )
"
$ *
!
" 71 "
% " # <+' ; <+ " "
$ " # " !
# <+ # <+$ * "
" ! "
)' F
# =++ D #
"
)$'
'#
$
!
!!
$*
"
#
4
<+% "# ) %
!
& !!
'
L ) " "
# (;%
) & " "
# $ " # # & #"
*
*
(;&+*
'?
!
$
" #(;
& * ##
(;D=++%
! " "$
'
'"
!
#(;&+':
) #
$
##(;&+$"
!
!#&%
(; '
;" $*
$
$ ##
# %
!
&' (
* ! #
#<+
#%#<+"&
#"""
#
"
##<+%
"
'
4
Reference List
4
0
3
7
4
0
3
7
&$?
&M'
%
'(
G
7793/%7'
2K+$L
5&'@
/ )'(
2"
H #
7793/4%40'
52$M"
*52'(
"'F77933/%'
F?T$ M 2K$ H' (" / ' F 779
30/0%'
:
"&$
5M$: K'(
##
# #"
!'FH
@
"309/4%'
" $ ( 5$ 2$ ?
* M' "
/ * #
#
! V5 H+!
779/3%7'
2$2L$- K$@H$M H$?
'
#%!
"
!
#"
"
'F77974/40%0'
?
*M$F
"MH$M
!
%5,"M$E K?$M
KH$H
&-
'
%
!
"
" '
334937/%'
@ F$ -$ = ($ ( ;$ - " 5$ ;
H ' 5
!
G
!
# & &
: &)" ? @
" 2 2
"'
F333937/%'
?
*M$F
"MH$-
$F2?$M",;&$:
M-
'
#"
"
'F77793/37%3'
HK$F
"MH$?
*M$F
H$M",;&$@5
'
#"
* " # "
" "
"'
("@
"7790/07%07'
F
"MH$?
*M$(&&$F2?$M",;&$K
'
%
!
"
! # #" #"
, ) !
! # =++%
"
"'2M
"779/04%0'
G 2$ ?
* M$ 2$ @ $ F
K$ =!
5 ' %
&%
#
!
"'&
77490/0%4'
& K$ -* $ " &$ ? 5$ G
* $ " K ' 2!
%
!
"
"'FH@
"7749/%4'
&L$(F$F"H$
&;$M
:;$=5
'&
'
M
#'?5H
339/%'
F
"MH$?
*M$F2?$M",;&$@5$ 2'
%
!
"
" *
"
'("@
"7790/3%'
: ($&
($M*"2$;&@$:
H$
2
'&
!
*
'FH@
"330977/4%43'
2 $ G" 2M$ (" &$ :
" &' M
# %#
)
#
'? 309307/%'
" M$ G
2G$ ?
?2' # #
#" " !/ #
!
#" !
' F 339
403/%7'
@
&-$ -
2M$ G
$ $ M 2H' & " )"
" '
3397/%'
F?$ K $ H' M
# %
'F77933/%4'
@
K$ +++$ 2$ " &K$ @
5K' (
##
# "
'FH@
"779/7%70'
!
"F
&2$
,
H$F "F?';
!##<+""
#"#"
##"#'F33900/7%7'
@
($ K$ ( -$ M H' &
" # # * #*'&?2O277973/7%'
4
4
Sickle cell patients are characterized by a reduced
glycocalyx volume
(Based on: Haematologica. 2008 Feb;93(2):307-8)
1,2
3
4
1
2,5
E.J. van Beers , M. Nieuwdorp , A.J. Duits , L.M. Evers , J.J.B. Schnog ,
1
B.J. Biemond on behalf of the CURAMA study group.
1
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
Department of Vascular Medicine, Academic Medical Center, Amsterdam.
4
Immunology Department, Red Cross Blood Bank Foundation, Curaçao, Netherlands Antilles,
5
Department of Hematology, Erasmus Medical Centre, Rotterdam.
2
3
Abstract
! !
!
!
!" #
$ !
! $ %&%'( )
! ("*+ ,
("-
(".!%&%'/)("-0+("( ("1.
!)2"(3+("1- 2".)4("(0."
Background and objectives
#
!
). ! !
! !
! " 5 $ ! ! " 6
!
!
!
!!
"2 % ! $
!
7 ! !
!
" 8
! !
!
! $ " 2 9!
$ ! "- * :
!
$ !
! ! !
!
"1
;
$ !
!
! ,
!
!
! ! ! !
!
!
!!
!
!
"<
("10"(=
! >
!
!
!
$ ! " 3 #
!
!!!
!
!!
! ! !>
! $ !
"2( 2*
#
! ! $ !
!
!
!
$!
! " !
! $
$
!
! $"
3
Design and methods
Patients and controls
! )% %'(&/ % ! $ ,!.
8!
?
!
8
!$
!"9
$
!
)
!
,
.
!*$
@!
@
@
!!
)!!!
A2*(%A3(
%
.":!
$
)%!%'(
. $
! $
$ !
)%
!%'/ ."8
!
!!!
>
)%8 ! %8 ! ,! . ! "8
!
$
!
!!$
!
?
! 9 8!
?
! 8
!" #
! $
!!
$
%
"
Measurement of systemic glycocalyx volume
#
! ! $ ! !
*(
)
$
*( . !
! "21 # !
! !
*( !
*( 7
$
! ! !
*( " #
! ! $ ! , !
"2 B! $ !$ ! ! 200( 1 "
,
-1(&!
$!!
! 1"
8
$$$
)1C!
.
!
$
!
!
!
!
&"
,
!$!$*1
! " #
! ! $ $
!
"D
7
!
)4
E2. ! " +
! $
! :8
):8@ B
? 5
$ 8. ! $ 2((((( $
!
!
" $
! )5. ! )%. $F
4)G2E%H5.&%"2(2
(
*( $ ! ! "21@2 -( 8 2( !
2 )D
@ ;DBI I
9
;
!.$7
!
"
8 2 2(( !
*( )
!
@ ;DBI I
. $ !
!
$
! !!12(21-(!0("#
!
*(
$ ! !> !
*(
"-(#
$
!!
! ) ,%32@
%." # !
! !
*( !
*(
7
$
!
!!
*(
" # $
! $
@ ! Analysis of blood samples
8
!
$
!!
!
!
"%
$
!
>
! ! 2(((( 1 " #
!
$
!0(((21
@$
!!
! (J"
K
$
! >
! )9
B
+
L#." D !
$
!
! $ !
!)
M-(C."-2
Statistics
$
! ! $ ! ,
)IK. !
$
"B
$
!
$
!$
N<#
! !
! $ !
$ ? <
L " ! ! " $
! !
$ ,
" : !
$
!
!" ?
$ $ ! "D ≤("(1$
!
!"$
!
D2-"("-)DII+."
2
Results
Patients and controls
#$
!2(!!$
%8)43.%8)42.$
!
!"
#
! 3 % ! 0 %'( ! !
! % ! - %'/ " #
!!
!#
2":
!!
"
;
8
).
?
&:
)%.
)%.
B?I
%&%'( 2-)3&0.
00)-- *0.
2&22
22()2(* 2-2.
)1 .
-2)-( -*.
%&%'/ )&-.
02)- 03.
0&1
22*)2(2 22.
()1 .
-0)-- -.
2(
*()- *-.
0&
2-2)22- 203.
-) 3-.O
-)-0 02.O
B!
%
)&+.
1"1)1"2 "(.
"2)"0 ".O
"1)"0 "3.OO
)C.
")"0 22.
-")-"2 -"3.OO
2"2)("3 2".OO
+
)2(3&+.
"()"1 2("2.
"()1" "-.
"-)0"0 3.
+
!
!
)L&+.
01)-3 1(.
--()22 -01.OO
22)2* 22.OO
:
%
)C.
3"*)*"- 2*".
-"*)("1 0".O
("1)("1 ("1.OO
8
!)
,
."ODM("(1
%&%'( OODM("((2
%&%'( "D
!?<
L ,
"
Glycocalyx volume
#
$$
!):
@
#
-." % !
!
! $
)#
-." #
$
!
! !
!
!
$
)!$."8 )
. ! $
! $ ! !
)4 ("*02@D4("(2."
!!
"L
!
!!
"
-
#
!
!
$
%&%'( )
!("*
)+.IK("- (".
%&%'/ )("-0+ IK ("( ("1. ! )2"(3+ IK ("1- 2". )N < D4("(-1." B
!!
1
"
%&%'( %&%'/ )+.
("*)("- (".
("-0)( ("1.
2"(3)("1- 2".O
%)&+.
2()2-3 -33.
3)3 2(3.O
2-()* 2*.
%!
)L&.
22)( 2.
2()2 2*1.
2()32 -*-.
8
!)
,
."ODM("(1
%&%'( )?<
L
."
0
Interpretation and conclusion
;
$ !
!
! " + !
! ! ! $ !
2
!
" 21@2 I ! $
!
! !
!
$
!
)
>
!
! !
." #
$
!
$!
2"21@2#
!
%&%'( )("*+.$
!
)("-0+.
%&%'/ "#!
$
!
!
$
7
%&%'/ $
!
!
$%&%'/ $
!
"
%!
>
!
!
7
"-0I
$
!
$!
2
$
! !
" %$
!
$
$
!
! !
$
"!
!
$
!
! !
! !>
!$ !
!
!"8
$
!$
!
"--
!
!$
$
!
!
"
8 ! ! ,
" 8!
$
!!
!
!
!
!
! "8
!
!
" 8 !
! ! !
!
$"
I$
!
!
>
!
!
!
" <
>
! $ !
!
!
"
*
Acknowledgments
9"P" B
! >
! ! ! $
" ?";
$!
!
! ! ! ! $
! " +"?"9
! 8"P"
!
!
$
!
"%"5!
!
>
!
!!
$
!
"P"P"B">
!
!!
$
!
"B"P"B
!!
!
>
!
!!$
"
1
Reference List
2
-
0
*
1
3
2(
22
2-
20
2*
21
2
2
2
23
-(
D?;
D"
!
"#
+
-((*@0*F20*0 20("
8PD
8<
"9
!+
58? 2
D
!#
I
!5
"I!I233@2F3 3"
PB 7
8? ? " ! 58? 2 !$ !
"8"%
"-((0@-F2(3 220"
?P
B;Q"
8
!
FD
!
#
"B!
2333@3*F2111 21("
N P ? B$
!
< " +
!
!
! !
$
!
!$
!!"
BP%
"-((1@20(F3*0 310"
< 5 % R! ?8 6!
9 ?" #
!
F
!>"D
8 9PD"-((@*1*F0*1 013
5!
B
B?5%P89"#
9!
D
8?!9!
"
-((0@3-F13- 13*"
7!B"%
!
"8PD233(@-1F* 1*"
N>BB"?
!
!
$
!
!
"
8PD233@-0F*2 *3("
88 5 % P89" 9
! !
! !
!>
!++"8PD%
D-((2@-(F2(12 2(1"
5 % 88 P89" 6!>
! +
!
9!
+
F
ID
9!
8!
"-(((@2(2F21(( 21(-"
B
$> 8 >$ 9 ?>
$ ?" I
! ! !
!
!
!!
!
!
"
?"
B
"233@2F 3"
<! BP P+" % !
! ! ! !
F "!"
2330@-F0* 03"
ID%B"
!
!!
7"8"P"D%
"D"-((@-3(F--* --1"
;
$!??7%+NP
"9!
!
<?
#
2
"
-((@11F22- 220-"
65%
?#
?
":
!
$!
)!
."8
"8"233@F2-0* 2-0"
;
$! ? %
#< ?+ " + 9!
8
%
!
< 9!
! 8 I 5" -((@11F*( *"
5 % B" I!
+ ?
9
!
+
<?
"
233@3F12 13"
5%B"
!
!
!
"
8PD%
D-(((@-F-1 -3"
N
BNB9!
?9D
++"8
$
!
$
!!
(
!2-1I !!"""8233@-1F2 ("
-2
--
-0
: I " 8 ! !
, >
! "
8"B
"233@-12F-0 -3"
9+P:P"<
"
!
$
!
!
!
"8PD%
D-((0@-*F211- 2113"
NN
7N"#
!
!
F8
$"+
-((@(F23-2 23*0"
Part III:
Pulmonary hypertension
Large and medium sized pulmonary artery obstruction
does not play a role of primary importance in the
etiology of sickle cell disease associated pulmonary
hypertension
(Based on: Chest. 2008 Mar;133(3):646-52)
1,2
3
4
1
E.J. van Beers , B.L.F. van Eck-Smit , M.R. Mac Gillavry , C.F.J. van Tuijn , J.W.J.
5
2
5
6
1
van Esser , D.P.M. Brandjes , M.C. Kappers-Klunne , A.J. Duits , B.J. Biemond
2,5,6
and J.B. Schnog
on behalf of the CURAMA study group.
1
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
3
Department of Nuclear Medicine, Academic Medical Center, Amsterdam.
4
Department of Cardiology, Slotervaart Hospital, Amsterdam.
5
Department of Hematology, Erasmus Medical Center, Rotterdam.
6
The Red Cross Blood Bank Foundation, Curaçao, Netherlands Antilles.
2
Abstract
!
"#$
% &' ( &&')*! (%
+
( ,(
+ ≥%-.! ( + &(+/
0!
%
1/&))'2&)3/'&)2&)34/
(%
+
+ (5$&)).&)3/
#$&).&)34/
% &&0/678*! (
'
( %6&)).&)3/
( '2$!'$!-$!('
/
&& # $!' #$! $! &)).&)3/ ( 9%#!% 6 &).&)34/ ( '
#$!' $! $! (' /
&& $!'-$!'-$!&).&)34/
( 9%2!% (
& /
( &(
(( %
: & & "' ;
&
+)*/ %
Introduction
!;
)*!
" #$ ( %< 7 ' (%<# )* ' & " +& & ,
%(+''&.
&
& ! & % )*' ( !' ; & &
' ; )*%5/2)+
+(
&
'(
&
2$&))
%/1'
&&
(
%:'
+')+
( & . & =
()*%
& +
)*/ & % 6 & )* ' ( & &%
0! & (/
%#'5 > 0/
' ( + ( ; & +
&
''(( %
#
Methods
Patients
+
+
.
:?:'@!')+
:'
@!8?A'@!(&
% 6 (B = )*' ( % 8" (B (
+'(&+
'
( -! . &
% C ( & +(% : ((
&(
+'
'
((%2 ( +( & )+ ! &=
+(
+:?8?% ((
*%
Trans-thoracic echocardiography
/ ( + =
( %-/ #%-/; % / ?/?' *
(/
( & / / /"' / (
&' & /& +(% 8 ( +( '++'//&;'
% D + ( & ( +(% ,(+ A!( &
( *
= " , + ( % A
+ ( & > = & = :! & +(&% &+(
&+(&
( )*% ( A E %- .% / ( (
( A+%#
.
!%*(8.:F%%
5
VQ-scintigraphy
0/
(
(/?>=/&
?'' @!
%6(=
" +( - +(' -2 "!% G
/ ( +
="+(
-
+('
-2 "!% 0/ ( ; :H/ & ( &+ (
(&
% 0/(;
+ 6+ 8& * 678*! &%&(+"
'
%% & ( & % &&
' ( + ( ( & ( &&%5 @"' ( ( & ( ; % ) & ' + & ( ! + &/ %6+(%D'0/(
; /
' ( + & & % & ( & ;& 0/
% * ( + &
&( ( &+ +(% ' & ( ; ( =+ B '
( & ( ! ' &/
' 5 % (
+&=(
% "
&
=+
=+!%
Statistics
: & ( /= 60A! (%
* &( ( ( ?/I/J %
*&(
((/=1C
"(
%1
=+
(
%1
&(
(
=+% 1 )
! ( % /+ ≤%- ( %
)(
&)))%%)))6''6D!%
-
Results
Patients
@+
(&'-(
%8/
+
(%1'+)*
'&))
&)3/' ( ' ( + )* &)34/&)%<1
&%
Trans-thoracic echocardiography
/ ( - +% +
+ (#$#
5$! &)).&)3/ # #$! &).&)34/
9%!!% A ( (B %. 60A %2/
%.!'%±%.'%-/#%-.% :(&)).&)3/
&).&)34/
%@
+ ( &( % @ / +
(&(%
&))9-#!.
&)9!.
&)3/92!
&)34/92!
/+
:!
#/5!
#5/#!
%
)"?B!
-B55
5B
%K
:)$!
5%$
%#$
%5K
(.!
%5%2/%2!
%%#/%#!
%
:!
/##!
#/!
%5
*$!
%#$
5%$
%K
&.D!
%-%5/%5!
%-%2/%2!
F%
D".D!
%%/%-!
%5%2/%5!
%
1&$!
%25%/-%!
%%/%!
F%
D*J.D!
5-#55/25!
#55/!
F%
@& 60A!% /+ & ?/I % K/+ & /= % :) 9
'&9&'D*9%
VQ scintigraphy
6#
(
% (&,
0/
%:(==
%
2
/&+ + ( % G
&/ +
&&!(
G
9%5-!%
: 678*/ 5 $! ( && 0 ' # 2$! && $! /
&& &)).&)3/
% 6 &).&)34/ 5$! ( && 0 ' #$!
&& 0 #$! /
&& 0 % A 0 ; ( 678* &( &)).&)3/ &).&)34/
9%!%
* & + 25 ( &' 5 ( ' ( &/ # ( ( &
%
!
&)).)3/
&).)34/
@ /+K
-$!
$!
$!
%#
6 $!
#$!
$!
D(
2$!
#$!
#$!
@&
!%K9/+&/=%
@ -$!
-$!
$!
/+K
%2
:
+((
=+
!&(
( @9-!( @9-!% /&
(&!
/ 9%9%
+!% "(
9%2!%A9<D9<)B:
9
"<:9<D9D<?9?<)D9)
<6D96
D<)9
<:>9:/&<D>9D/&<>9/&%
&(&
(
9%2!%@
=
((678*
&&(
& &+ (!% & (&
(&
( + + / + 9%#<
9%!% ( (!%
Association of VQ-scintigraphy with PHT
)"
(0/
&/
%:
(
&&0678*%6
' 678* (
&+&(
(( &!%:
&&0(
% :)
&%
6
( '
&&0(
(
&% ( ( &&0%
"
#$
%
:% : !' !' &= ! &= ! +( ( /%>%:!'
!'
&=
!
&=
!+(
+ ( & ( & +%
I ' & ( /& ( & ( ( 9%9%
+!1!%:
&)).&)3/ & 9%!
/&9%5!(&
( ( %6'(&
(&)).&)3/
( 9%#!1!% (
&).&)34/
& ( + % @ ( /
!
&(
(( (!% (
&( A
&
(!%
(/ /
%6
'
(
&&0/% &/=/
(
( 1#!%
&
%
7L/"
==+)8!
% 7 H/" + + + A%
(
(%K:
(
(
A%#.%KK:
( A&(%#.%-.( A
% M:
( AE%-.( A% (
&(&)).&)3/
&).&)34/
(!%
Discussion
: "#$
(
% N+ ' & . + )*% 6 ' ( + &+&
( 0/
%0/
(
#
++
&
'0
)*%8+
(
'
@+
+% I & % 1'
+(+
%<>
678*';
&&"-
2
( %: ( (
&&0/+"
&
'
&(
%5 ; & & &! )*/ ,
%
:0(
((
& &% ) ( &
((&
( ( % N+ ; "
& %@
'
' ( &( ' &(
(( %
++ AE%-.&+ )*'
)*/ (
(%<<#6
$
& A%8+("
(+ '(/
(
& A + %5 6
' 0
(
&
(& A%
:; '("
& +&+/%(+'+
&(
A)*'(
; ( %
1(+0
)*%I%0
2
'(0/
&%-6
+'G#
&&0
(
%26
2 ( ( ' + ( '(#
;
&
&&0% &"
&
+ A#%5.'%/5%!
A%.'%-/#%-.(
( AO%.!% '
)*' ' & ( & )*/ % (+' (+ '
&&
+&
%)
&&'((0
' & "% > &+' 0 + &
& & ( )*% I + ( ( &;%
6';
&
+ & ( )* ( %
&/&;
&+)*/ %
Acknowledgement
*%%'*%:%N*%%)&'*%G%I%D?%:%G'
(&"%
References
#
5
-
2
#
5
-
2
N(? ')+'P?D%
A1*(
)*%@8P?5<#-!B2/-%
:G6')@'*NN%
% :P
?5<!B22-/22%
:G6'?N'P)%
(B
%>P2<#5!B/-%
8:'A(;8:% &%><!B#2/5#%
>/
&%:G6'
?*'
A(;8:%>P%<#!B#/#%%
?A1'N(? %B('
%>P-<5!B55/525%
? 8:' & *8' L L? % B % >
P#<#!B#-/#2-%
:,?7'
P':G%&
(%
:D&?<-!B5#2/55%
7
8'8PA%%:A+A
*<#2!B-/
-%
LN'A'1%) & ((
)*%:PA
?<--!B2/2#%
)*'>:'?1:%*
+&
&
;
(%:P?2<!B/%
P )A' N P ' ? )% & :
: %2<#!B-5-/--%
?N?'N*')%)'8*'*:
B:8+/>N%5<2Q
!B5)/#5%
@' N&& )P' I R % /
+ : && & %P@?<5-!B2/25%
?A1'G?:'?)% )+
+/+
"
(%>P<#2!B#/#-%
)?P')>@L%):)BA %>
<5-!B---/-2%
I*1':+:%
+678*)%
+6+
8&*)%P@?-<#2!B#/#%
1 :P' ? G?' 1 1% + + %#<52!B2/2#%
(*A':'A8%7&)B/&+
''%:P<#!B2/-%
7)'>&*P'AI1%?6)*//D8"
A1
8*%@8P?5<###!B2#/255%
#
5
-
2
)>8')':%)% (/*
( % : 6 ? <
5!B-2/-%
>?'(;:' :%0+
(
(+*
%P:-<2!B#-/#2-%
GD'P')(P>%
*
%P:<#!B-5/--5%
7' N( ? % B ' ' %7@:-<-!B/2'+%
I>G'>)G'>8A% &&%:P
<#!B/#%
G @' ?( >' )+& * % + .0! ( % : P 5<
5!B5/5%
::'?A1'P?D%1:)*
(
%:PA
?<-!B/
#
5
No association of the hypercoagulable state with
sickle cell disease
related pulmonary hypertension
(Based on: Haematologica. 2008 May;93(5):e42-4)
1,2
3
4
2
5
E.J. van Beers , H.M.H. Spronk , R. van Oerle , D.P.M. Brandjes , A.J. Duits , J.W.J.
6
4
2
7
1
van Esser , K. Hamulyak , H. ten Cate , M.R. Mac Gillavry , B.J. Biemond ,
2,5,6
on behalf of the CURAMA study Group.
and J.B. Schnog
1
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
3
Laboratory for Clinical Thrombosis and Haemostasis, Maastricht University, Maastricht.
4
Division of Haematology, University Hospital Maastricht, Maastricht.
5
Department of Immunology, Red Cross Blood Bank Foundation, Curaçao, Netherlands Antilles.
6
Department of Hematology, Erasmus Medical Center, Rotterdam.
7
Department of Cardiology, Slotervaart Hospital, Amsterdam.
2
Abstract
!"
# ! ! # $%
&'
!!!'
#''
$
% ( # ! )$*( + ( ! &( # ! ! ,( +-, ( , '
&#'.* '
./ $
0!
!!'''
$+
! ' '
$
-
(
!!'#''
(
!1$
Introduction
3 /4 ! ' # #!!$!,
$ - ( ! ! ( ! ! '$*-(&
&'&!
&!
!
&!
56 # ' & $/, '&( ! 2
& # ' 56 ( 7
'
*!*#'(
7
,&
, ! $2 '&( 7
('&'(
' 56 $8((9 # 7 ( ' ( !( & & ! $ :&( , # '$ ) 3( '
!
7(
&&!+-,
!$,*!
' &'
!' !,$
2
Design and methods
' & ! 2 ! # !'$(2:!
1 !' & ;5 ;5 ! *$,*$9<( ' ,& ! ;5=/<$ , ' ' ' ;5 &
! $/ < $ ' &' & "
&' & + : >
:
$
'
'!!#$
Collection of blood samples
? ' # ! & ' &
@ ( / 8
8$A
$:
!!
?#(
B(+ $''&!
!
3C$/;: (,D
$
Endogenous thrombin potential (ETP)
+
' ! ?5( :(
0 '7
!
E
9,'!
+;(FG(#() "
'
/9<8 ! $ +! ! ' ,
( ' : ! ) 8 H:
< < & >>,
!!
$)
,
>>(2$/(:*(<A?+(*$:
I,C,C,+,+:$
+ ' $-!(H!''
'&*H!,('&*
HJ*
,3$:'
!
/2D ! $ ! !
' !
' ' : * /2D "
!
' )
$ ' ! * H )
' ! !'$)&'&!
&K
(
> (#(3
#(
!#$'!'!
#!!!$$#(?5(:$ '
>&
'4$
Assays
!' # ' !
L L
!M*)M* (
!,>A-+L?(:
(
C ( , >7 , ( ?( N A! (
&,&+-,K(7(? $
Statistics
) ( & O, ' ( ' & OM, $ +
' ,"
-6; $ ?' !!
'':,%P$)
#
!! '
$,&
Q$'!*$$*(
-((-A $
9
Results and discussion
!
'$F
3
& ! ' ' ' ' ;5≥/$< $ + <OM, '
!!'!$P!
3
'!!'''
$0!'
(#!$
+ :K!
<A )4 AP<A ;5< <O,
0,
./* .** //*,8 /*8,* K*
K
$8$9,$ $8$/,$9 9$$,2$ $9*$*,/$8 /9/*/,* 8//2,2/ $9$/,*$/ R
*$*$,*$ R
<OM,
0,
.* ./ *9*/,/9 /*, *K9
K*
2$$2,2$ $$/,9$ $$,$ /$9$,8$ *//*2,/8 *2*/,*8 *$$/,*$* *$*$,*$ &K
H< )M*< 8$2/$2,$ /*8,/ /$9*$9,$9 *22/,8 /$*$2,$* */*,/ /$2/$2,/$2 22*,9* )K
+-,-P< ,H< $$9,*$* **8,/2/ $2$9,*$2 **,82 $$,$* **/*2,// *$/$9,/$ *22,8// !K
)< 22,*8 **28,* ,* 982,* &K
,< 39<A //*2,82 /*8,/22 /2*,8 *9*2,/* /*2,/ */*,/8 *22,/2 /9*,/2 K
>:S *9*,*/2 *9/,*8 829,/9/ /*,2 >,::S 89,2/ *9, 2992,/ *299,/ 4:
/$*$/,$9 8$/$/,$/ $2/$8,9$* 8$*$,$8 >,:S /92, 22,2* /*89,// *9$99,9* 4'
/$2$,$2 $*$2,2$8 *$9$/,8$9 *$,$9,$ RK!Q$ '0,$.
$A.A
$>.>
')8H+P:S $>,:
.>'!
$>,.>'
!$
0 !! ' ! ' # ' '
$ )
( ' ! !
;5 &
$ ;( ' β,( ! !7!( !
!! & ' ' '
(3!,&
'
3
!'! $/
?
(!1!,
&
#&
!
&
,
$
+
#!
3
&#
#('
3
&$
- ' !( ! <β, ! ! !
# ' * $ & ! # ! ! # & ! ! ' # 3 $2 !#
!
( ' ' &
& $
+
<O,
<OM,
A
;
A
;
A
;
!"
,$/
!!
$*
,$*
$
#
)M*ρ<A +µ<A ,H< >:S >,:S >,::S Q$ Q$ $/ $* $ $98 $8 !#
,$*
!#
!!
,$
$//
$ $/
Q$ Q$ Q$ $ $* $ $/ $2 !
!
!!
#
,$*8
$
$*
Q$ Q$ Q$ $* Q$ Q$ $*2 $* $*/ "
"
,$**
$
,$2
,$8
$*
,$/
,$*8
$ $ $ $* $2 $9 $ $*2 $* ! !!
!
,$*
,$*
,$
,$9
,$/
Q$ Q$ $ $ $ $* $8 $/ $ $*
,$*
,$
,$
,$
$*
$/
,$
,$/
$2 $ $* $8* $8* $2 $ $/ $ '#!!',&
'#$
!$.<A (A.P<A (
;.
4 $
- & # $ -( !O,'$(
7!#
' ,& $9 && $ % ! 3
! & &,$ '&( & ' ;5(&!&;5
!!,
!(*'!#!7
'
! $ - ( ' !! # ' '
$ ! ( 7 # ! ! & ! ! '$* '&( & # ! ! , ( ' !! ! ( 3 &(*
!!$
*
References
*
/
8
2
9
*
/
8
2
C' :( & 5( B :A( 7
#
G( B)( : N( ?' ?( %+( 0 B(
> -( A+( ?#' %( +0( ; C( F( F )$ ;# ) ! ' # $ 0 > B : *8L
/9 K,9$
B ;( : ( C B$ +
K "
&
&'$>
;B$*0&L* K999,8$
:>+(
>(GG:(C:(';(B(+N(:#50$
!
#K
$?B
!*/L*/* K/9,/$
+1 :F( B( + N( ( :$ '#$+A:*L* K8/,88$
F >( > B;$ # $ + ;& ; 92L
/ K,9$
++(:;)(B:A(&,&+:(;
AB(
A(
B(%(0B(
+& 0+( & 5( ( C' :$ )
+ ! # '
$+B;:*2L*,89F$
& ? >B( & >#, ?A)( : C& :;( & 1 B)( & > B%B( ?1 :(
N,N
:( +B( ? ?B( B?$ A 7 ! ! # $($
5#>$
#$0>B:*8L/9 K2,9$
B?(
+B(:
#)+((;1;+(?1$#L&&'$
0B:*8L* K/8,/28$
+N-(F>$
#K
3$+B
!
:*/L9 K2*,2*$
B ;( C B( : $ + +
$*L/* K8,*$
) %( A7 B$ $ B
!
A:999L/8 K,$
( N
)+( A( 5# >( ) ( ;! $ K ' & $ + B *L 9 K2,
2$
C(C!(
,?#;(IC(A-(N
:(??;(
N$-!
& K & ! !!$ *L* K2,*$
A -:( : BB( F :+( : N:( ! ;;$ ! , & & & ! '
$
998L9* K2,2*$
?0G(;+N(
:B$#K$?*L
9* K/**,/*//$
+;(&)(>(C:(:
:(&B)(?
(#$
K$**L
8 K2,*$
B?(:C&:;(&I+(:1B(;1;+(
+B((?1$
!#$+B*8L2 K*,/*$
/
9
*
*
8
: ;)( C' :$ # K ' ( !
$?B$*:L*98 K889,8$;&'$
& 5( : ;)( 7
#
G( ; G0( # ( > -( :( %+( ; ;(
?#'%(F(NCB(C':$!
#!!
'#$B+$*2B/L898 K82*,9$>
*2B$
; ;( ? A( ( C' :$ "
! -&
>3
K+0&:!
$B+:+*L*9// K/,*$
Association of asymmetric dimethylarginine with sickle
cell disease related pulmonary hypertension
(Based on: Haematologica. 2008 Jul 18. [Epub ahead of print])
1
2
3,4
5
6
P.P. Landburg , T. Teerlink , E.J. van Beers , F.A.J. Muskiet , M.C. Kappers-Klunne ,
6
7
3
4
1
J.W.J. van Esser , M.R. Mac Gillavry , B.J. Biemond , D.P.M. Brandjes , A.J. Duits
1,4,7
and J.J.B. Schnog
on behalf of the CURAMA study group.
1
Immunology Laboratory Department, Red Cross Blood Bank Foundation Curaçao, Netherlands Antilles
2
Department of Clinical Chemistry, VU University Medical Center, Amsterdam.
3
Department of Hematology, Academic Medical Center, Amsterdam.
4
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
5
Department of Pathology and Laboratory Medicine, University Hospital Groningen, Groningen.
6
Department of Haematology, Erasmus Medical Center, Rotterdam.
7
Department of Cardiology, Slotervaart Hospital, Amsterdam.
Abstract
!"!# # $%
"$ & ' $
# #
( ) "* +
#$$
$#
* , * # !
, # -
(
$
$.-
+
$'
"#
&
+
*
#(
$ +
!/!01-$ + 2,$3(45µ$/$6,
7
*3(8-3( $
+
29,3(8µ$/$6,3(89-3(48 23(3 *&#
$#
(,
.- +
*&# *
* % &+ "#
23(55,23(35
23(:,23(339,
"# ,
23(8,;3(33
$# ! !* &
"$ & '*
$#"(
Introduction
$
# #
$# 53< & ' +*
'&
#(=
!"!#
#
-"
$#
!&
$
#$
*&
' (9 * $
# # "
, " "
$* * !* !
""#(5
=#+
"$
&#$$
$#
* , "* !* &
$* !"!#(:>8 , + -$#-6-
* #$$
$#
* , " &
$ "
!
-
$#&
*
!#
*$#
&
= &
$ #( ! $"#
! # ?#$ #$, !# $* ( *
!#$#
*$#$#
+
$#
#(4@"$
"!
"
&
$&
" ! ' $ +(> $ & # + "*
+
+(
Patients and methods
Patients
$@$$+
"!&
$'"#
&
+
*
#
+
($
-"
& *
* % &+ "# =. & 9(8-9($/ =.A5$/
"#, $
#-
# $ + *
*+=.*(5$/ (#
+
"+!#
$ $$ "
!7# "+ " $ @
$ ( *" +
&
$
(#+
+
&
&'(
Laboratory determinations
$
&
*,,+
$
!#*-
&
$7
$*
# + &
"# !,3 + $&
$*
(
-#&&&"
+;5<&
$($$+
$!#-*
$*
#+#
$ "? $
( $ ! "
$- .- " +
$ * $&
B =C
#$D (
Statistics
E+*
&&
+
+-)#D(F
$ ' && + ( -" ;3(38 +
#*&9(3(9,G,*,G6 (
93
Results
Patients
# & 9: !/!0H-$ , &
# *
*
!/!01-$
! (
$
"#&+$#++=.≥5(3$/ (D&#
#
+&&
!+++*
$*,
!'
&(
+
9
*#
559-:: 999-89 3(3
I&$
4I99
8I5
=.$/ 9(3(5-9(5 9(9(4-9( J$$* 99-9 5:59-:5 !$$/6 8(8(3-4(9 :(:(9-8( 3(38
!F< 3(44(-(5 8(9(9-:( 3(5
6D/6 54533-88 885-:4 3(39
KF=JJ$6/$ 893-8 9344-9 3(3
3(83(89-3(48 3(453(8-3( 3(3
µ$/6 3(:3(:9-3(88 3(83(:-3(5 3(3
µ$/6 :859-84 :4:-49 3(94
*µ$/6 84:9-44 84:8-8 3(:
µ$/6 954-59
993-59
3(44
µ$/6 9349-98 934-95: 3(:
µ$/6 */
3(:3(44-(3 3(53(9-(8 3(:8
*/
((44-9(: ((:5-9(48 3(:
*/
3(953(-3(5 3(983(-3(58 3(:
.-*/$6 33-95 8:9-3 3(33
$+
*
7
*(-";3(38
#
*&( J=* "
# + $ ! $& E
7 ! 7 # $
# # ! & * "
&+
!
(JJ'
&K-&
$$I
2(95+*:3-* /
$
,
&$I
2(35+*:3-* /
$
(
9
ADMA, SDMA, amino-acid profiles and endothelial activation
$ +
*&# !/!01-$ + $
+ ( +
&&
&
,
*,
,
!+++
(
$.-"+
*&#*
+! (
E$
$.-
+
*&#
=.
23(55,23(35
23(:,23(339,
"# ,+*&
!+
.- + 23(8, ;3(33 ( # *& & +
$*! 2-3(:, 23(33 , !F< 2-3(83, 23(3 6 "
23(8:, ;3(33 +
!
"( , , ! , +
*&#
*$
&
KF= 2-3(44,;3(33,
2-3(3,23(43,
"# ( + *&# , $*!
2-3(8,23(33 ,6
23(5,23(3: ($*!
+
*&#
=.
2-3(53,23(3: (
+#*&
!+ * =., , $*! , 6 " .-"+ ,+
!KF=+
*&#
*
2-3(8,;3(33,
23(89,;3(33,
"# (
99
Discussion
$#
"
!"!#
&!"**!#&
$*! * "# & $%
$
#*# &
(9"
#
!
*?$
*
&
!# !* "#(4 $ " (:>8 G # + $
& $ + ,$#"(
$ +
*
+ +
,+$!#*&
!+=.$
( + +
" $
" "# !# # $ (:>8 #, + * $# ? !# * $ *$#
$#!$
$&$#
*
'#
-"
#
(&&
$
# "
!* $ ! = "# # +L
*(9-: * &&
!+++$$,"$
-
$ *& -
! * &
' & "
*(4 # $
& $
≥3(4:µ$/6 + *# $
# # #+
$!-$!(
! + " #&(8>4 G
#
$.-"
*#
$
,*
! $# ! $
!
" & ( !# , $ .- " *&# =. ( K" * & ", + ! * #? $# "*&#
!"#&"!
+ *
$
" "#*$"
$(
""$
&
*"#
&!#+
*
+"
,!$
(> G
+
!", &&
*/
!+ + $# $
+ ! , * $
* "#( 95
$
$
&
**
&#*$
*
*"#(
G
*
"#$$!
&!'
&* !
*
(,
*
?
$
* * &
$$ ' +
$
-"
(9 +"
, *" !+ $
#
#
=.,&"=.
&#&-
#$
#&,93+&'&
*
?
+*&#&&
(
'*
,
&#
&"
#
!*&
"$ & ( , $ & $# +
"$
+$'!+$#
"&(
Acknowledgment
)*
&#'+*
&*
M*(
9:
References
9
5
:
8
4
3
9
5
:
8
4
K+,".,M6,?'N,MF,
O,($
##
'
&
&
+'(+@*%
&$(933:,94>583I48(
=F,K+(
'*I+**,*
$&$
##
(E
%
&$*#(9338>9I::-4:(
.'# @( $
# #
' ( + @* %
& $(
933:>583I8-(
6!
* , ' , ' F, M, * ME( $ & #$$
$#
*,*
#!
,
"'!
&
*&
($
%
&$*#(933>
(
*ME,
',"
%F,M,'F($"&#$$
$#
*
, * # !
, " ' ( &
$*#(9338I99-4(
)' @, $ , )* M, )* P6( #$$
$#
* "
, *
#
&6-
*$!$(
*$!$(
933>I53-(
O M, E-E*
, K, -6!&&
M, ' , F
, ( #$$
$#
* $
# #
( , $!, "
!*#(9338>98I::-(
'
-%
, $#
F, ?!' , E
$ , =, =, ( #$$
$#
* $!$! $
# #
( $
%
&
#
$(933>4I8:-43(
"E
@M,"@'-$E6,K"
#=,"%F,"@
M),E
%,(6
*
$$ ? $
# # !
# & $
# $
*# &
'$
#
((933>
(
',%"=M,M*,"6+(
$&
*,#$$
$#
*,
#$$
$#
* $ $ !* $ !# *-
&
$ 7
$*
#(#!$
#(9339>535I5-(
M* , ' ( # & #$$
$#
* $ !# 6 * $
$(#!$
#(9334>585I9-(
, , ' , $ , * , '$
O( @&& & #$$
$#
*
&
$"
(#
(9335>:9I8-3(
6
M, , E, #-= M, ' , Q
E, ( & $#
*
$!$$
"
$(
$(933>5I-935(
' , , ? , ?$ ( = & $ * # !
,
* "#, # "# &
$
#
#
($M#6*#(933>99I:3-(
#''
), ' , +
, %
, %'
$ , '+%' , ( $
#$$
$#
* # + $-$
' $ ! "
$- .- +
$--$
&
(O#
(9338>4I9953-4(
M,.'
M,&K,
$M,O,6,(E
#&+-$
#$$
$#
* "
' #* F #( (
933>4I54-5(
98
93
94
*ME,=%
=,K"
#=,,E
%,M(#-.-
$
"+'(&$*#(9335>9I3-5(
OKM,
#
,E'+
),M,),
6,(6"&!$
" $ + ' + $
# #
,
*#&,$
#(E
%
&$*#(9338>53I:5-85(
=, O KM, %'" , )* P, E'+
), " ., ( #
* *
$!$, $#- $
# #
, $
# ' ( M$(
9338>9:I-3(
" ., =F, ?' N, = N, ' , @
G, ( #& ' &
&
+ ' ( M
& $
* &
*#(933>:I:9-(
9
9
Cardiopulmonary imaging, functional and laboratory
studies in sickle cell disease associated pulmonary
hypertension
(Accepted: Am J Hematol)
1,2
1,2
3
4
E.J. van Beers , E. Nur , C.M. Schaefer-Prokop , M.R. Mac Gillavry ,
5
2
5
6
J.W.J. van Esser , D.P.M. Brandjes , M.C. Kappers-Klunne , A.J. Duits ,
7
2,5,6
1
and B.J. Biemond
F.A.J. Muskiet , J.B. Schnog
on behalf of the CURAMA study group*.
1
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
Department of Radiology, Academic Medical Center, Amsterdam.
4
Department of Cardiology, Slotervaart Hospital, Amsterdam.
5
Department of Hematology, Erasmus Medical Center, Rotterdam.
6
The Red Cross Blood Bank Foundation, Curaçao, Netherlands Antilles.
7
Pathology and Laboratory Medicine, University Medical Center Groningen.
2
3
Abstract
!
"
#
$
$
%
&
'
#
(
)
*
)'
)'
)
+, '
)
)
- !'
)
./
*
./0. *
0. #
/
%
1
23
*
$
#
(
#
)
))
#
(
-4 5%3
6 %
1
#
(
*
)
)
#
#
%
(
#
7"
*6*89
"
*6*8:/
%
.
)
#
+,'
)'
-
)
*#
#
#
%
)
'
*
'
#
./ 0.
(%
))
*
(
)
)
#
*
)
'
%
Introduction
#
$
;
*
(
'
*
%
(
(
!
)
<
<%
&
(
#
'
)
)
*)
%
-'
*
);
(
%
&
!
"
$
%/
*
'
/((
)
)
/
)
#
%
&
'
)
#
'
*
6
))()
%
+!
))
)
'
)
/#
*
6
(
)
'
)
%
1'
#
)
*/
)
*
%
#
(
)
)
$
%/7
<
)
)
$
(
#
)%
Methods
Patients
(
$
()
)6
1
=
1='
1'
. '
(
1'
. +
=
-'
. #
)*
%
)
)
)
#
)
)%>?
&
#
'
#
)
$#
$
)
'
)
* #%
<
#
*
)
@
*
)
%
&
#A
)
@
)
B )
;)
$
* '
$/
* '
*8:/
*8/'
)
2
#
%
+!
#A
$#
)(
'
*(
C '
)
#$
6
)
*
)
%
#
(#
*
(
*@
(#
(
1
=
+
=
%
#
#
$%
Trans-thoracic echocardiography
/
)
#
*
#%3
=
#
))
D
#
(
-4 %39%
6'
#
-4
≥6
)
/(
%
#
#
))
#
-4
)
(
%
6
) %
1
+ 1 (
)
E%
%
Laboratory testing
0
#
#
(
(
*
(
#
#
%
)
*
#
)
%
)
)*
* #
#
)
@
)%
-)
*
#
)
'
3
+1
'
#
*@
/2F
%
G(
0.
./0.
(
#
+1/
#
;
1**
) -
) '
(%
Chest x-rays
/
!/
#
%
#
*
()
(
*
(
!
)
/
1 )'
$
/
%
(
#
!
!
)
%
#
;
*#
*
*
(
)
)%?
High Resolution Computerized tomography
1
-
#
*
'
'
#
%/%3
'
(
(
%
&)
#
()
&=1H %
1
-
)
#
(#
*
!
)
*
%
-
#
)
(
*
)
%
&
'
*
#
)
@
'
)%
1
*
5
(
*
%I
Pulmonary function testing
!
(
+4 '
(
4 *#
+4
4
+464 #
)
)%
B)
(
#
*
)
B )
(
#/*
)%
)
)
*
!
B'C
0 '
(
(
41 )
(
(
*
!
B'C
0
41 #
)
)/*
)
@%
/
)*
(
#
)
(
#
)
#
B'C
B'C
41
(
)*
(
)
16+-
%2
0
'
)
B'C
#
!
)
(
)
16+-
%2/
1
(
(
*
B
*#
3
(
#
+464%
1
*(
(
*
+464
*#
3
(%
Electrocardiography
#(/
)
'
3
6>
(
46
#
*
+,
%
)
(
'
-'
G
G-
'
!
'
G-
#(%
#)
)
)
(
#
A
)
!
(
:
J
'
-
#(
4
-
#(
4
)
I
/'
#(
)
K%3
&&'
&&&'
4%
+)
(*
#
(
*
#
()
*
%
1
*#
()
#
(
*
D
(#%
7
Statistics
1
*
#
)
@
) #%
*#
)
#
#
=/<
L
%
)
*#
)
#
#
/@
M
!
#
%
0(
#
#
$
%
=/(
#
#
)
%
1
/
(
E
%3
#
)%
=)
#
)
)
%
#
*
)
%%
&'
)'
&B %
3
Results
Patients
&
'
(
#
)*
#
23
)(
#
%
'
(
)'
*
*8/'
#
)
)'
#
(
)
*8:/
*%
*
*
%
L
!
#
*#
#
#
*
%
!
*
)*
)
(
*
)
*"
!
# %
%
*68/
.
*68:/
.
)A
.*
1)
=6
1
" C
!
" 7/3 ?A?
3
7
/7? ?A?
3
7
3
?/33 A
/ A
+)
A
-4
6 1
) " B
(
B
(
)
" %?
%?/%2 3
/2 3%2
3
72/33 / I
/ %
%/% N
2
/ N
%7
3
72/37 7
/I 7
/ %3
%3/%3 / 3
7?/37 2/7 2
I/ %
%/% N
/I N
3%
72
7?/3 /7 3
/ 0
A
)*
6B *
" B
,
6 NN
B
L6B
I 3%
7%/3% ?%
%/%7 %
I%I/% 37/II 37
I/I3 3%?
7%/?% %2
3%?/I%? %
?%/%3 7I
/2? 2
/3? ?%?
?%/%? %
%/7% 2%
7%?/%2 2
/I 3I3/?7 I%
?%I/I%2 %
%/%? ?%
7%3/%7 72/7 I/7 =$
A
0.
)6B I
2/3 7I
I/2 / / .//0.
)6B 7/? ?/3 /77 /7? NOE%3
(
%
NN$
,/
A
%
!
#)
!
7/) 6
'
A
%
!
#)
!
7/) 6
%
?
Trans-thoracic echocardiography
/
)
#
I2
23
I
(
%
&
3
" *
%
C
#
/(
*6*8/
)%
@
#
)
)
O%? %
.
/
)
(
#
*
#
%
*6*8/
)
I
*6*8:/
)
*
))
D
#%
!
)
%
1
*
#
*6*8:/
)
#
(
#
*#
#
#
#
#
)%
-
C(
#
-4P
C(
)
-4P
%I
%I
/(
E%
E%
&
(*
;
0
,Q
/%N
%
,
/%IN
E%
)*
(
/%7N
%7
-4
%3N
%32
P
&
(*
)'
)*
(
)
%
N;
0%
Q
*6*8:/
*6*8/
%
1)
)
!
)
%
I
Laboratory testing
-
*
)
*
%
<
;
)'
*
)
*#
-4
.0.
(
#
O%
O%3 ) %
#('
*
*#
-4
0.
./0.
(
#
;)
*6*8/
*6*8:/
%
&
(
/
(
?)6B
#
'
2"
#
(
./0.
(
(
2" '
7"
2?" O%3 %
)
)(
(
)
(
#
I7"
7?"'
(%
#
))
#
*
./0.
0.
(
#
*
-4E
%3
6%
./0.
0.
(
(
#
)*
(
O
/
%73>
O
%
*68/
)
O
/%77>
O%
*6*8:/
) %
0.
(
)
#
)*
(
*68/
)
O
/%?7>
E% %
0
)*
)
)
#
)
./0.
/(
)
%
1)
-4
*
%
.
)
*#
./0.
0.
(
*
%
1)
!
/(
))
./ 0.
(%
Chest x-rays
!/
#
?
#
)
#
7
#
%
#
)
- *#
#
#
'
#
-
)
)*
O/%33?>
E% )
B O%77A
E% '
#
0.
O%72>
O% ./0.
O%?I>
O%7 (%
#
*
#
;)
*6*8/
'
*
*6*8:/
# %
2
High resolution computerized tomography
1
)
3
-
#
)
(
#
(
)
*
(
$
%
#
)'
'
(
)
*#
#
-
)
#
%
(
/
*
-
#
#%
.
)
*)'
'
'
'
$)
*))
-
%
!
*
-
#
#
)
@
#
(
%
&
*6*8/
)
*#
#
#
#
-
*
%
*68/
*68:/
.
.
.*
7
0
$)
0
7
0
3
=
2" " %% %% ,)
7
?" 2" " " " 3
" %% " -
I
" 7
3" 2" " *
Q
?
B*
(
Q
%% %% $
*
3
7
Q
*Q
?
.Q
%% %% $)Q
2
%% *
*
#
)
*
-%
*
*#
*$ )
)
(
)%
*
(
)
)
*%
Q)
#
'
'
(
%
.
)
#
*#
#
#
%
Pulmonary function tests
#
I7
#
I
#
) %
/
33'7" (
(
#
7
3'7" (
*(
)
%
#/
'" %
.
)
#
#
#
*68/
*
7 %
Electrocardiography
&
I7
)
#
(*
#
I
#
) %
&
*68/
'
-/!
) #
#
#
(
?
/7 7
/37 K%3 %
&
*6*8:/
'
-/!
) #
#
#
(
2
/3/
7 7?
/3 K%3 %
.
)/!
(
/%
#
-/#(
4
)
I
'
#
%
)
*#
#
#
#
)
%
!
"
*68/
*68:/
.
.
.*
2
4
I2
?3/2? 2
I/2I I?
I7/II 2
2/I +4
I
?3/2 II
I/2? I
??/I 2?
I/ +464
2/2 3/7 / I/ B'C
0
??
3?/2 I?
?I/23 I
?I/I II
?I/2? B'C
0
41
2/I / 7
7/7 7
/ 41
?
?/I I7
?2/2 ?
3I/?? 2
I3/ B
I7
?I/2 I?
I/2? I
?/2 I
I3/ .*
)
!
#)
16+-
(%3/I
4O
(
>
+4O
!
(
>
BO
)
>
B'C
0O
*
!
)
)/*
)
@
)* >
B'C
0
41O
B'C
(
(>
41O
1(
(%
7
Discussion
*D(
#
(
))
%
#
(
)
)%
(
#
*
*
%/'
1
#
7'
@
#
'
)
)
)%
(
)
#
%
&
)
*
)
%
&
'
3
-
#
(
*
(
1
#
#
(
-
%
(
!
'
)
)
*
*#
#
#
%
C
'
*
#
#
%
-
*
#
)
*
#
!/%
)
*
%
0
(
*(
)
*
$
);
%3/?
*#
#
#
/
)
(
#$>7%
#('
#
)
(
?
*
#
I
*
#
#
*
*
!%3
#
;
*
/(
%
$
)'
)
)
(
*(
)
/
(
)
*/(
)
#
%
(
+,
#
)
)
(
/
#
+,
)
*#
#
#
%
1)
+,
)
(
*
*
#
?/'
$
+,
)
*
!
*
(
#
1
*
*
)
(
*
$
*
+,
)
(
)%
'
+,
*
)
%
./0.
0.
(
)
-4
#
#
(
#
./0.
0.
(
*
>'
)
./ 0.
0.
(
*
(*
)
(
%
#('
)
!(
#
'
)
*
*#
./
7
0.
-4
)
)%
'
(
)
./0.
(
)*
,-%
(
./ 0.
;
)
)%>
1
*
*8:/
(
)
#
'
#
-4
#
#
'
*
*8/
'
!
*#
%
<
!'
#('
(
#
*
*%
.'
*
./ 0.
(
*
)
%
;'
#
-'
#
)
*
))
#
(%
&
'
)
./ 0.
(
)
#
*
%
&
)'
#
)
)
./0.
(
#
#
(
)
(
*
)
(%7>3
1
'
./ 0.
(
*
)%
NT-proBNP (pg/mL)
10000
HbSS/SB0
HbSC/SB+
1000
100
10
1,50
2,00
2,50
3,00
Tricuspid regurgitant flow (m/s)
3,50
#
#)
*#
./0.
))
D
#
(%
7
&
)
#
*
%
'
#
$
'
*
*
%
#('
$
.
(
)
(%
'
*
$
%
'
I"
*
-4
)
(
*
%
#('
(
(
#
'
))
)
)
(
)%
'
(
#
#
/(
'
)
*
)
$
#
%
#('
(
'
)
)
#
)
)
'
'
)
#%>
&
'
$
)
#
%)%
-4
%3/%6 '
)
)
#
H/'
-
!'
)
+,
(
#
)
)
'
%
1'
*
)'
./ 0.
(
*
)
)
%
7
Supplement
High Resolution Computerized tomography
)
-
;
)
- #
*
'
'
#
%3
(%
&)
#
()
&=1H %
1
-
)
#
(#
*
!
*(
*
%
-
#
)
(
*
@%
0
)
#
(
#
(
*(
*#
*
)
)
@%
!
-
*
#
)
#'
)
@
#
%
@'
-
*
#
@
#A
1 (
O>
O>
O>
O( >
0 * O>
O>
O>
O( $)
O>
O>
O>
O( >
!
$
*
O>
O
(
*
>
O
(
*
*
3"
((
>
O
3"
((
+ *
O>
O
(
*>
O
(
* >
*
O>
O>
O>
O( %
&
-
*
)
O>
O>
O>
O(%
&
'
#
3"A
1 *
)
#
)))
>
0 ))
;
)
#
(
(
*(
$) >
;
(
(
'
)
*
*
>
>
+ *)>
*
%
'
)
*)
#
(
*
* '
*
#
$)
#
%
.!'
)
@'
*
#
(
>
#
'
)
*
)%
#
*'
)
*)
(
*'
(%
1
(
*
%I
#
$
10/
#
77
*
*)
*'
('
%
$
*
(
10
#
E
'
/%3
'
%3/
!)
%
#
!
)
'
$)'
*))
)
(
)%
'
(*'
*
#
(
)
*
)
;
))
$
3
! %
73
Reference List
7
3
?
I
2
7
3
?
I
2
7?
,#
='
(
4'
R
=B
%
-$
#
$
%
.
+)
R
=
7>
3 A22?/23%
1)
S&'
.'
,
,
%
$
%
1
R
=
7>
I A??3/??%
B='
R
R'
,
B
%
#
$
A
*
%
1
R
2>
2 A/3%
1$)
'
T
'
0*)
%
-)
(
$
#
%
?>
I7 A77/77?%
1
1'
=
-'
R
=B
%
1
$
#
%
1
R
-
=
I>?/72C%
0
+'
,'
&
%
)
+,
%
>
A3/32%
B
,'
,
.'
$
%
4)
*(
%
2>
23 A3/3I%
=
.R'
S
&1'
=
-.
%
&4/-
A
1
-(#
%
>
27 A/7%
SD;(
0S'
&(
0U'
1(
1
%
.((
((
(
)%
+
-
R
I>
A3/3?%
,
RB'
0$
0'
,=%
)
3
#
$
%
1
R
)
I2>
7 A/?%
=
-'
1
1'
*)
=
%
./
/*
(
$
$
%
R1=1
?>
">? A/2%
4$
+'
,'
1
%
#
$
6*
A
#
./
/*
%
)
I>
? AI2/I7%
#
-'
+/=
'
B
%
$
A
$
'
'
%
1
&
=
>
32 A?7/?%
-'
1
=1'
@
=%
,
-
./
/0
.
(
=
4
%
R
1
)
)
I>
7 AI/2%
$
R'
U*
<'
0)
R%
)
)
1/
/
0
.
4
0
L
.)
)
+(
;
%
1
R
)
I>
2 A7/73%
1)
S&'
=
,'
R
%
#
$
A
)
%
0
R
?>
7 A/3%
-'
S;
-'
,
B-
%
L
(
)
#
)
%
=
)
<
B)
,%
2>
3 A3/3?%
=
.'
-C'
4)
,
%
)/*
*
!
$
)%
+
-
R
3>
?7 AI/I3%
<)
R'
RB'
1
%
)
(%
+
-
R
3>
? A3/3%
=
=-'
$
R'
0
4
%
%
+
-
R
3>
? A/2%
)
-1'
R
S%
10
)A
)
)
%
0=R
>
7I7I A/7%
(
S'
-'
<
1L
%
)
*
$
%
+
-
R
?>27 A2/2%
7I
72
Dissociation of exercise tolerance and pulmonary
hypertension in patients with sickle cell disease
(Submitted)
1
2,3
4
1
M.N. van der Plas , E.J. van Beers , H.J. Bogaard , R.P. van Steenwijk ,
2
1
B.J. Biemond , P.Bresser .
1
2
Department of Pulmonology, Academic Medical Center, Amsterdam.
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
4
Department of Pulmonology, VU Medical Center, Amsterdam.
3
Abstract
!"#
$%&
'
(
)*
$'
'
%&)
+$
$
(
%&$
()
,
-
' %& ' ) * $
) ' "."# $ ) /$ $
(
0
(123-
$$'''
)
4 (
'
(
' 123-) 5
' $
' $
)/
(
$
0
)
6%&'$
$
0 $ ) *
(( ( $ %&0 $ $ )
Introduction
% %& 7 0 ( ( ( (0 8 $ $ $
) (7 %&-
)
"# $ $$
$
)93 6
0 '
-
$)%-(
$
0 (
%& $
$ $ ()34
0(($
$ %& )"/
$$
$9
0$
(
1:23-
*0 $ $
$ ) 6 %&0
' 0 0 09; ( ) * $ %& ) / $ ( ( ( *0 ' ( ' %& ) *$
0 ' $
$
*
%&$
)
* $ ' ' )
Methods
Subjects
/ %%0 %0 %<=- %<-0 $ ( $
8 (0 '
( $ /4/4$
'
($
)6
'>(.
$
*)
'>(0 -
?3'$
? ' $
) * (
' %% %< ' (
( $
0 ' (
%%<=-)/( '$
)*
'
'
'
'
$
$)
Study design
*'
0
-
)'0$
(
(
%&
'0'
'%&'
$
)*
$ '
) &( $ 0 $ ( ( $
0 '
(0 ( $
() / *'$
(
0'3'$$ )
Trans-thoracic echocardiography
*-
( ' $
$
)@ /
( (
%&-$0
$'$((
A$
'
*B1 $ 3) ⋅- ( $(
8
"()*
'/
$( $
'
'%&)3'*B13)-3)⋅-
0''*B1≥")C($$$
-
- )3
'
(('
/'*B1
( $)"⋅-).
3
Laboratory testing
1
$
(
0-
0
00D&005*-
E5''
(
( D $ &*/ ( ( $
$
(
,) 5*-
E5 ' &*/-
( ' -
B
&(
)
Pulmonary function testing
%
' $
( F( 4% $$
0 +7(0 G
$
,10 $
,1 ' 61) *
( *D ' ( F( 4% E
0 +7(0 G) *$ $
$
*D020
H
$$
&
' $
$ *D02 ( !3# ' !# (
0 ( ( 8) *D02 ' $
(
( /*%CB% ) %
0 ( *D02 '
(
/*%CB%()-3
Cardiopulmonary exercise testing
%
* ' $
( ( $ / *
%
)" E$0 $
'( $ $
(0
' (
( ' $ 1:0 1:230 1:230 0 () +
' +0 ( ' $$
' ' -
) '
( ' $
) '
(
(
$/*
%
)"**$
$ ( ( ( * 7 1:23 ? .#
0 ' 1:23 1:23I/*9 ? # 0 (
- - 9 J D J
#( 8 $
231:C1:23
?")-@
"
Statistical analysis
&! %&)/'$
'%%%
( %%% ")9 (
0 6D) : $$ ' $
0'$
'
-($)4 (
$ ($ ' *B1 '
$
*B1
)/-
'
7'(
$$0$
(0$
'4+'
)6
$$$0(
'''*B1
)/-8'
' (
(
)/- ?)'
($
1
1:23-
1:23-
$
J.#
/
1
23-1:23CB
1:C1:23I/*
1&C1*
23
/-23
J#1:23-
J#
?C
JD
J#
J.#
?"
?)3.
?)"$
(J
J)@
J)@
Results
Patients
,$-
%& ' ( $
)*'>'
$ $
(0 "
' $
*
$ A
$ ) $
( 3.)@ !
)@ ) 3) ! ")@ ?)0
$$ '
) &(
(0'
$
'$
0'*B1
$3)
3).⋅-0 )E
7*3)
Trans-thoracic echocardiography
>
/(
G4C,
%%
%
%<=
%<
D
>
(
C
5*-
E5(C
3@-L
"C3.
33
3
"
;)!)
!;
$
#>
,1
.")"!)@
,1
.).!);
*D
.)3!3)
*D02
@)!")
*D02C1/
).!3)3
L(
* 3#9 0 $0 ( " ! 3) $
0 ) *B1≥3) ⋅-) 2$ " '
0 . *B1) $
(
0 ' $$ ' ' '
* ") * $ $$
($ ' (
(
" $ %C%<= @
$3;%%C%<9K);3)
Pulmonary function
B $ $
( ' * ") 2 (0 ,10 ,1 *D
' ') / $0 ' *D ' $ 0 ' 33 0 ' " $)/ (*D02'0
$*D02 '
$
$
)
($ ' 10 ,1 *D '
)
4
0 1 ,1 ' ($ (
1
K)9 ,1 K).9 ?)) /$ $
(
($
$$
$
'$
'''
)
Cardiopulmonary exercise testing
*-$
$ ."# ' (1:23-0)) '.#
$ )6
'
0 1:23- ( 1:23I/* ' '0 ' 0 $$ ($ ;") !
3);# @") ! ;)#0 K )@0 .)@! )3# @)! @);#0 K)@0
9)
*B1?3)C
*B1M3)C
>
5
"
/(0
G04C,
%%
%
%<=
%<
D
>
(
C
,#
N
C
&E
C
*
E
C
O
C
D&C
5*-
E5(C
3!
.C3"
3
"3!3
C
@
3
;)3!)
.)"!.);
)!)"
).!3;)@
)!")
3)..!)@
";).!@)3
.3)"!)"
)"!)L
.)@!;);
")!33)@
).!)
;).!)"
).!)..
")!3)
").!").
$
#>
.;)!)
,1
.)@!).
,1
.3)@!)3
*D
@).!).
*D02
.)!)
*D02C1/
@")!;)
1:23-
3.)!)
1:C1:23I/*LL
L($$$$
*B1?3)C- ?)LL
)
;
@).!3)"L
@3).!)"L
@3)"!3)L
@)@!;)
;).!3")@
;")!3);
3@);!")
' 0'($
'1:23-
(
K);0?)9,(30
$
(
$ $$) 4
0 1:C1:23 0 $
$ 0-;9. ' '
,()4 (
(
1
' 1:23-) 4
> 3K)0 ?)9 7 <K).0
?) )"0 ?) ) + 0 (
1:23-)4
0
($
'$
'*B1$
)
B
$
%%')E
*0@
'
K@0 $
K30
$
K0
$
K0
$$
K")
@
Discussion
6 0 ' $ ( ' )*-$
$ 03#
$'
$
)
) 4 (
' $
$
( ) * (( (
$%&0
$
$ )
/
(
($
$(0
' 1:23- 1:23 0
( (0 1:C1:23 )-@
6 $
'
)/'
$
0
(1:23-'($
(
)
/ ( * $ %& ''
$
"
) 6 0 ' 0 $ ' )
*$
0'
'
)
,
0/
-'
($
'%&
'
'
$
(
)36
'0 $ (
' 0 7 -
- 0
'
'
7 $
)6(0/
#
$
*B1
)36%&0$ (
$0$ '
'( )3*
(0
(( 0 $ %& 0 - $
)/
(
'
$
0
7 ( ) * ( '
$
0'
( )/0 $
$0
0 $
.
$ $ %& )/ 0 ( 7 (
$
'
($
)*
$(
$4
$$
$
-
$ $ %& ' 0 ;- '
)33 /
( $ 0 / ' *B1 ? ") ⋅-0
((($ $
0 $$3"
$
)3
/$'
(
$
),0 $
$(
$(
)
%
0(7
(
(
$
%& ' -
- ) * $
$( %&)
' 0 '
$
' $ $ -
$$ 0 3-3@ ( ' '
)%''
'
%& $
0 ' $ $ ( 7
'
($$$
)
6 0 ' $
0
$
)*$(
'
-
%&'
)E
$((
$
%& $ $ ) / 0
' 0
$(
'%&$
$
0 $
)
Acknowledgements
* '
)F) % & $ (0 / 4
0 O $ /0 * 5 F)E) %
( & (0
4 0 B
0 * 5 $
$ )
;
Reference List
3
"
;
@
.
3
"
/( N60 4
G0 F
%0 2A 20 %
&0 /0 2( ) '>
()EF
3;F9">-)
G'4*0 % 10 F
4D0%7 P0 F,0 4 N0 E
' E0 +/0 5
F%0
60 D/0 E' +0 % /50 B
( G0 20 2( ,) $
$
' ) 5 ( F 4 3 ,
3;9">..;-)
D 4*0 B
7'( E0 4%) ) / 2
3@/(9.>;-"0.)
+B027,0/%&0+F0
$$G0N,Q0%B0407B0'
B)/
$ '
>
$
()
33F;9;">"-3)
, FF0 G( F0 G
/0 ' F0 %0 P P0 & %0 & 4B0 % B)
D
(
$
$
')/F
3.,
")
N(%0+7&,05
1G0%(4)/
$
'
)/FB43;F9@">3;-)
E F0 -% ED04 G 4B0 *A,0 F+0 EA &0NN40&/F0E
EF0%
(FF)D(-7
$ ( $ - -
)3.49""">;;-3)
E( 40 '7 /0 1 */0 E
$$ BD0 G
( ) H $ '((
(
' &
)F/
./(9;3>"-;)
F)D(,
))2$
>E'%$
9@)
4650
B201(G0F
&0 G0E
10E(
,0B0
/0(0G$
0
F0FB04NB044B05 A&02,0
(
B0+(F)%
$(-
$
()BF32
93;>@3-")
+(F0FD0
/02,0E
10E(
,0B0
B0(0 G 0 G$
0 F0 F B0 F
&0 46 50 4N B0 4 4B0
5 A&0(
B01(G)%
$
$( )BF3
%93;">-33)
44B0
F0E
10E(
,0B0
/0
B0(0 G
0G$
0FB0F
&046504NB05 A&02,0(
B0
1(G0+(F)%
$
)BF3/(93;3>"-".)
/*%C/ % () / F B 4 3" F
9;@3>3-@@)
&R/
7
G0 G
D/0 BD0 B( BB0 &B %D0 , ,0 &7 &B) $
( $
$ A ' )
.@F93>@-;3)
B 4%0 77 F0 ( 40E( E0 + N) G ( (
) F / 3%9.">;"-@)
;
;
@
.
3
3
33
3"
3
3
3;
3@
;3
% QG0 F0 27 BF0 + N) ( ' )
3F39>3-")
+ N0 F0 % &P0 %( +)+)0 + EF) $ *( 6
),
)D
+S+93)
6'*05(50/
40%
*0%,0N
%0*0G
P02P0O40
5 50 4 N) / $$ $ ( $$'
)
3/(9.;3>..-3)
D/0 +
N,0 4 G/0 B D*0 E 0 G E) '
')/FB43349;>"-;)
//04
B,0F
4D0* -& /40BDF0D0F0
+05
F0
/ 5/0% 100G'4*)
$
$'
)/FB43@F9@3>3@3-)
T410&+0&%0%%/) $$ $
)/F
[email protected];>""-.)
4
B,04%0N
GF0EBF0//0B
4B0D0
+05
F0
0% 10
20G'4*)%$'
)EF
3/(9"">-")
27BF0B
G0F0%QG0+N)$$
$$
$$
)F,3@%9>@-3)
%
,50 / /0 & /0 F0 4 /0 H 6T0 550 B
%N0 E
' +B0
%0 NA B) %$ 1( $
$
)/F
3.493">".-;)
%'
ND0O7F0N
'4F)&
(-(7
' $
) 4 % 4
3.
/9>B@@-B.3)
/0 /7
/0 F60 %
60 %
0 T(
40 E D0 D %4) ( 7
'( (
)FD(*3/(93.>.""-)
&
0 FE0 G&0 + /O0 E 40 E
B4) $ &
((7
)E
FB
@,9";3>3"-")
;"
;
Summary
Samenvatting
E.J.van Beers
1
2
1,2
Department of Hematology, Academic Medical Center, Amsterdam.
Department of Internal Medicine, Slotervaart Hospital, Amsterdam.
Summary
! "
# ! $ #% &'(!
)&#*#
%%%
% # ( '+,!
- !-%
## #% ' # ! - % ' # # # )! . #(#/#*#
% #*# /% # (#%'
# !0 # % # '!-% 12#*#3
!.12 #*#
/#
/**!4#*
# % 12 ' # #
!$ #% 12
' ! 5 ' '# # ' ' ) )2!6'(##*#/&
' #*# #' '
' # ' #! - ' % #3 ''#' #
#*# *44
!
- % 3! ) ' #
' # ' #*# ' #'!.'
' #
#*#!
- &!
3''%
*#81!5
81 & ' ' # ' ! - # 81 #*# % & % ' #!881 #%'
81' '!2%*#
81##%'# ! 4% ' & 9: ' ' * ;- '#! 5 & ;-* ' ' *# 81 !
5 # 81 #
/#!
2 ' ## # # &! ) '#%/%
' ' &% '* % % !#%'#
#*!7 - &% 3 ' & #! . 3 & ' ' '* &
%&#''
#*!2##
'#*#/%
#% '#! $ #% # ' ' # '(# # ! - & # ' #'
#!
7
51$5%
3# !
5 1$5 ! $ #% ' ' & ) '#'!< - ' = # 1$5 !
>& = # 1$5 ? '%'#%%&
# 9* 2 ' 1$5 ! 2% # # 282% &'%#'1$5#'
'*' 1$5% 282 # # !6 4 # * 1$5 '# ?
1$5?
)
#*#/
'*3'
'7
' <
#282!
># # # 1$5 ' % 1$5 1$5'
#! 2 1$5 &
% &1>5 1$5! - & ' & '
# ( &
' % # % %
'% ! . 1$5 # & ' ' #%1$5!
5' 1$5
!$ #%
#*#%
' 1$5 #*# # <
* 1$5 % 1$5!
5 282 1$5 )
'#'1$5)'#' 1$5##!2%282
#1$5 '(
!4# %1$5'
' * % 1$5 ' 1$5 #'# !
9
Samenvatting
5 #( ( 3 @ #( ' 3 #'(#!# A#'
3 # @ A 3#3 # (! # ## 3 # # ' # # ! ) % 3 (( #*# @ 3 % ' 3( '( + A, 3 % % % ( (3
'(#@'!
-# #@'!-
#3 # # @% # 3 #3!
- ###3
A @ ) '#! B ( # / # #*# # # #
#!/##*#%
'(##3' %
' # # 3 ( (!0 23 # # 3 # 3 ( 3 A @ # 3 # % A#3#(#!
- ##A
12#'#((#*#
#A'3!$'#12'(
A @ ( #*# # # '##'( #('
(% ('# # #! "( ' # #*# 3
12 #3 '# ' #
! 5 3 12 ' ' (! '# '# '# 3( '(#'#@))2!6
>'(##*#'#
'##!>(
3 # 3( # ' # @C 3 '( '(###!-'##
' # #
''(3A@(#*#
(+,#@ * 4 4 !
> # '
'3#( A3 #*#
!'' #A
@#''#*#!
$ # 3 # @! @
# #3 % 3 ! > # # 3 & 3(
3'(#@!
-#( #@A
' ( #*# ! 5# #% ' # '! $ # ' # ' '(! $ ##*#!1 # ##
#%'#'
# '! D '# ' ' '(
# # # ;-!3&'(#;-*('
# ' '( @! #
'( # # # 3
#+,#' '(#(
'!
> ( # ' '( # # '#&!) 3'#
' '' ( #
' &C#( #'
' # ' # # ! ( ( # #
#*'(@!7
- 3 A @ &#!B &*##
33(#@3A'(#
'&#*'(@!
$ 3 ' # @ # '''#/##*#%'(
# 3# 3(! E 3( ( ' 3( # '(# #
3# ! - 3 # &# (
3(# '@#!
- # @* 1$5
'!3#@##'(3A '#
! # @* 1$5 # '! > '( # #3 # ' '' # & )!< $ #
'''3'(#1$5'(@!
F'#'3'(#1$53(?
'% ' ( 1% A 3 &G#!9*233('#@%
@* 1$5 (! > # #
282% # )*% # 1$5 '( '*'
1$5%0'(#3(@!6DA
#(@*1$5 #'#?
@*1$5?
•
##'(A@)C
•
/##*#C
•
#3 ' # A
C
•
#7C
•
' <C
•
282 9!
0
$ #''@*1$5#
#(#(%'((1$533##(
1$5' ##3!1$5
# &
1>5 # '( A 3 1$5! '( HH A ## #'! !3!
1$5! $ # A # 3% 3 % # # % # #
' %# 3!3'#
33( (#1$53# (#
!'#((@*
3 #*# % '( A 1$5 ( 3 1$5
#( #(% 3( #' 1$5 #'(@ ((!
282 1$5 '( @ '( # )*
'''(#!(282*
' # 1$5 # @ 3( #! F 3 1$5 '(
@*A ' * ! ># #
3%3#'(1$5%'(A@*
1$5# # !
6
Reference List
IF!5?/!1-**!!!
) J?BK%<9!
1%"'I%L.4%814%%'8$!8-
**M>&L4>!)>I8<<6C0090?0<*66!
0
II%MML%L(L2%#(41%842%2I!) #!2I$<<7C
7?*!
6
I"%"(18%2I%L(L2%84%3?!!
!2=L(?F@%99!
- ! ? # / '# ' ! 99
C<?1!
2%2%BE%$8I%LI%')!'*#
#!"990C9?7*70!
L % .% F $% # @# 82% >' 8B! 5 &?
%%#3!1299C!
7
18%)1L!*!5M996C06<66?060*09!
<
EBI%B 85%'8$!?
#'!"L#99C?0*6!
9
4'$.%M3I!1!)>I8996C0
?
*
!
M I% ) 8% 5 "% 8*L I% 8 8% N$ " ! '#!)899C0?<7*90!
8 MI% . B% M % M I8% $8% L8 ! ># - $&*- 1 $!
990C97?6<0*6<7!
0
*( )% 8 4% 13' 2% " % L% $ L ! 2
'' ! 2 I L 899C?
6*9!
6
I"%55%#(41%2I%842!1#
282%&'%#!2$99
C
76
?7*7!
8L4%E82%8%"%81%#F%>-%$M2%.2%
)I1%EBI%B 85!##*#
& !"I$99C0?0<O0
!
Dankwoord
Dankwoord
!
" # $%&
$'
$#&
$ (# )%"* #$+
# ,*"-" $
..&&$/&
0' $ && 1
22% &&&$
" 0
$
. &&
&$) $
3 &&$&
&&1
(&$$ .$4$5$ 60% /70 $8
/700$
-$ %&0( 0$
(&$-$'$2$) &&
$
&$$ ($"$ : &$$ 5$"$2$ - $ ($ . &$$ .$
4; &$$ -$-$ 4 && $
6 &&,*"-"0
$ / $ -$*$-8<= > &$$ "$2$ & $ 5$"$2$ - $ $ (
4 = 3 > $ 2$?$2$ 6
$ -$$ :0: & $ .$ 4; $ "$ * = *
>$'$-$'$%$*$)$:$'<&'$
=00> !$$'&$"$8$$% "<:
"8=>$
"& # $ . &$ @ -&"44=*< 1>
$
"& 3 $ 2 - &< "- A $ ' = B>2= >2=A>
AB
"&$(-('2. ( .$ . < #$
9
"& $ - % * . * @ &$ $ "$
% $ + $+ 5"%%"@ 1
'/ <<3C/
5D0E @ &< &
<<30&&0 &C- <<C * 6(0C $ ?$2$4 CF%%<
"*% G = > = >C'4C(
8 - , & $ $ + C ($$@ ($?$5 2$'$5 < &0$ $(&$"$'$E. => $
& $ + &$-=
> < = > -3 =*0 8<<3 > - % = & > % ?
=HI IJ> ' " =%& >
5 = &&B> - = > 5
= > @ = > 5 = K
>*=3 >2<=0
> < = & > . = > -
=L
?!5.+&1>:4<= 4(%>@=
> ? =< > % * * *
= >8=>6= 0C
<0>%= C >"
*+*-")'=+2 >:
- . 4< - ' - = <<30=&>=>=>> ( )
- " : : < - % % " - - (? -
-&$2$2$($:6$8$"$-&(&$'$*$./.02
%06&= >$
6N $+"-
& ' 4 ' $' $
-<&$
4 &
$
. 0&C
1
4
2 $ & $ $2 $'& $
M
O
Curriculum Vitae
Curriculum Vitae
!!"
#
$%&'(
) $ $ $ $
$
'
*$+,-./"&0$
+ 1223 $ $) $ $ 0
%
%4$
&,$
$)
4
+&5122
+
$)
6"
7
8
7
.(
&$("5122
9'. $ ( 0 0
$&&*&&5122
(
$
6-
&
,($
.(
$)
+
© Copyright 2026 Paperzz